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Abstract!
 
Background 
The World Health Organization (WHO) defines medicines regulation as the 
“promotion and protection of public health by ensuring the safety, efficacy and 
quality of drugs, and the appropriateness and accuracy of product information” 
(1). Medicines regulation is a key function in the realisation of the right to 
essential medicines. However, a satisfactory level of harmonization of regulatory 
activities has not been achieved in the Southern African Development Community 
(SADC) region as yet. 
 
Objectives 
The study evaluated the current status of medicines regulatory harmonization 
within the SADC region, as well as explored perceived barriers to regulatory 
harmonization and potential strategies to address these.  
 
Methods 
A cross-sectional exploratory study design with qualitative techniques, as well as 
an inductive approach was used. In-depth, semi-structured, face-to-face interviews 
with interviewees from the SADC Secretariat, the African Medicines 
Harmonization (AMRH) Initiative and the Southern Africa Regional Programme 
on Access to Medicines and Diagnostics (SARPAM) was used, involving 
secondary formal qualitative approaches to identify the emergent themes, was 
utilised initially. A questionnaire was formulated and adapted using secondary 
data collected from the face-to-face interviews, then piloted. Questionnaires were 
sent to senior members of all 15 regulatory authorities belonging to SADC, 
including registrars and deputy registrars. 
 
Theoretical and analytical codes were identified from repeated ideas, concepts or 
elements. Codes were grouped into concepts, and then into categories. Trend 
analysis was conducted, involving an in-depth analysis of patterns. 
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Results 
Barriers to regulatory harmonization in the SADC region perceived by 
participants included i) deficiencies in governance and leadership within the 
SADC Secretariat, ii) human resource and technical capacity constraints, iii) 
limited financial resources, iv) lack of political will within SADC governments, v) 
lack of intra-SADC relationships, vi) risk-benefit analysis differences in 
assessment of applications and bias according to local population needs, as well as 
vii) different guidance documents and legal frameworks among member 
countries. Strategies identified to address these included i) using other 
harmonization initiatives as models, ii) application format harmonization and 
African Union (AU) Model Law adoption, iii) redirecting focus of harmonization 
to information sharing and technical matter rather than complex legislative 
frameworks, iv) regulator initiatives of harmonization instead of SADC secretariat 
reliance, v) World Bank Agreement adoption, vi) human resource capacity 
development and vii) convergence of guidelines instead of complete 
harmonization of all regulatory requirements. 
 
Conclusions 
The findings in this study suggest that it may be necessary to redirect the focus of 
harmonization to more readily achievable activities and aim for convergence of 
guidelines. Regulatory harmonization is possible if barriers to it are addressed. 
 
Key Words: medicines regulatory harmonization, SADC, barriers
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Chapter!1!–!Introduction!and!Review!of!the!Literature!
!
1.1!General!Introduction!
1.1.1!Background!to!the!Research!Study!
%
The United Nations (UN) states that “the enjoyment of the highest attainable 
standard of health is one of the fundamental rights of every human being without 
distinction of race, religion, political belief, economic or social condition” (2). 
Although a complex matter, most countries have entrenched in their constitutions 
the responsibility to ensure that all citizens have available the highest level of 
“physical, mental and social wellbeing”. This includes the “entitlements” of 
access to public health services and protection, the prevention and control of 
disease, as well as access to essential medicines. 
 
Medicines regulation is a key function in the realisation of the right to essential 
medicines. The World Health Organization (WHO) defines medicines regulation 
as the “promotion and protection of public health by ensuring the safety, efficacy 
and quality of drugs, and the appropriateness and accuracy of product 
information” (1). Since the late 1990s, there has been a worldwide increase in 
innovation of pharmaceutical products, as well as increased access to new life-
saving treatments through availability of generic products (3). 
 
Capacitated health authorities are required to regulate emerging technologies and 
alternative health products, in the interest of public health. Drug development for 
priority public health diseases, such as the human immunodeficiency virus (HIV) 
and tuberculosis (TB) that affect developing countries is lower than that for 
diseases prevalent in developed countries. For example, in a study of 1393 new 
compounds brought to the market from 1975 to 1999, only 16 were developed for 
tropical diseases and TB. Drug research and development for these products 
should be promoted in the interest of public health and require efficient regulation 
to allow registration and availability in the market of developing countries (4).  
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Another example of a neglected disease was that of Ebola, which caused a rapid 
outbreak recently and resulted in the need to rapidly develop and regulate a 
vaccine (5). As a previously neglected disease, it gained publicity in 2013 through 
public outcry over lack of adequate treatment and control in Central African 
countries where it was spreading rapidly.  
  
Likewise, the regulation of medical devices and in-vitro diagnostic agents (IVDs) 
are becoming a priority in many countries, which previously lacked the capacity 
to regulate and control these products. In order to regulate these products 
efficiently, there has been recognition by some countries of other countries’ 
decisions to allow market access. For example, the Food and Drug Administration 
(FDA) of the United States recognises capacity constraints in its own system and 
allows market access to medical devices and IVDs which are registered in the 
European Union (EU) (6). 
 
A study to assess the regulation of medical devices in the East African 
Community (EAC) was undertaken in 2012. It was found that the regulation of 
medical devices was generally weak, and that regulation pertained mostly to 
devices for priority diseases such as HIV, malaria and TB. Due to the lack of 
capacity to regulate medical devices of the regulatory authorities assessed, other 
research organisations and in-country laboratories were mandated to regulate 
these (7). 
 
The use of traditional and complimentary medicines is often the most affordable 
and accessible healthcare option in many parts of Africa (8). The regulation of 
complimentary medicines has become a concern for many countries, due to the 
number of products entering the market of poor quality. There is the risk that 
these products may be substandard due to poor compliance with Good 
Manufacturing Practice (GMP) standards or that they may be adulterated with 
other substances (9). Complimentary medicines practices have also changed in 
modern times from the sale of a single substance to a mixture of different 
substances, which presents an even greater challenge in regulation (10). 
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Since 2011, complimentary products in the EU have been required to be licensed 
with a Marketing Authorization or a Traditional Herbal Registration (11). 
However, in many developing country settings, including sub-Saharan Africa, 
these products remain unregulated. 
 
Cheaper labour costs in developing countries encourage an attractive 
manufacturing environment, while some regulatory authorities are concerned that 
this may be at the expense of quality. Many have argued that a lack of resources 
and corrupt practices are contributory factors to weak regulatory systems and 
oversight in these countries, leading to a knock-on effect on the quality of 
medicines available worldwide as well as an environment where counterfeit 
medicines are readily available. For example, it has been estimated that Nigeria’s 
medicine market is comprised of 40% counterfeit medicines (12). 
 
In a systematic review conducted in 2013 on forty-four prevalence studies on 
counterfeit medicines, mostly in low-income countries, it was found that the 
average prevalence was 28.5%, with most of these medicines containing 
insufficient amounts of active ingredient (13). The FDA estimates that over 10% 
of medicines on the global market are counterfeit, leading to inadequate therapy 
and poor public confidence in healthcare systems (14). 
 
Medicines enable the healthcare system of a country to meet its public health 
mandate. However, medicines regulatory authorities in developing countries are 
struggling to keep up with the increasingly demanding regulatory environment for 
pharmaceuticals. This is largely as a result of limited regulatory capacity and the 
need to ensure access to safe, efficacious and quality products (15). 
 
Substandard medicines may lead to drug-resistance and inadequate therapy. This 
also has the potential to impact adversely on the quality and safety of 
pharmaceutical products, leading to increase in availability of counterfeit 
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medicines. Furthermore, the availability of priority medicines to treat the specific 
burden of disease in countries may be compromised (16). 
 
1.1.2.!Regulatory!Environment!in!Developing!Countries!
 
Many developing countries have poorly developed regulatory systems, procedures 
and processes to ensure adequate quality, safety and efficacy assessment or 
evaluation of medicines and other health products. This includes limited access to 
quality control laboratories, poor regulatory standards, lack of trained regulatory 
personnel and limited financial resources. In a situational analysis conducted by 
the WHO in 2010, it was found that 24% of countries in Africa had “basic 
regulatory capacity”, 33% had moderate capacity and only 4% had capacity 
comparable to that of developed countries (17).  
 
Furthermore, the capacity for the assessment of safety and efficacy of products, as 
well as on-going pharmacovigilance, is also lacking. This is hypothesised to be 
due to lack of technical capacity as well as resistance from stakeholders who 
benefit from low standards of regulation in the market (18). Improving medicines 
regulatory capacity requires human, financial and infrastructural resources, which 
are often lacking in developing countries (1). These themes were tested with 
stakeholders in this research study. 
 
The limited capacity of countries in the developing world to regulate medicines 
has resulted in a number of cases of poor quality medicines being made available 
in these markets. It has been proposed that, due to lack of sufficient regulation, 
some pharmaceutical companies producing medicines for the developing and 
developed world may provide a sub-standard product to developing countries as 
compared to developed countries. This may include sub-standard packaging and 
inadequate amounts or quality of active ingredient (19). 
 
Another challenge with the availability of medicines in many developing 
countries is the “Western Approval” barrier, where market approval from a 
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“stringent’ regulatory authority such as the FDA or European Medicines Agency 
(EMA) is often required before less-established regulatory authorities will 
approve an application (3). This has a major impact on time taken to approve 
registration of products and affects market access, especially for medicines used 
for diseases endemic to developing countries and not necessarily Western 
countries. This may become a barrier to harmonization for developing countries, 
as some require this approval while others do not take Western countries’ 
decisions as primary sources of confirmation of quality and safety of medicines. 
 
Many developing countries are largely dependent on the importation of medicines 
from the developed world. When exported to developing countries, there is a 
concern that these medicines may not necessarily be scrutinized as much as when 
available locally (3). Developing countries need to work towards using regulatory 
decisions of other recognized authorities, while still maintaining autonomy and 
the ability to assess applications independently (20). 
 
Although growing, pharmacovigilance activities in many developing countries, 
including sub-Saharan Africa, are severely lacking, with the first 
pharmacovigilance units with membership to the WHO’s International Drug 
Monitoring Programme (IDMP) being Morocco and South Africa in only 1992. 
Adverse Drug Reaction reporting remains low, which continues to highlight the 
weak regulatory systems of many countries in the region (21). 
 
Currently, 33 pharmacovigilance centres in Africa are members of the WHO 
IDMP. Although many African countries have been the primary contributors of 
safety signals, such as those for the combination antimalarial agents, amodiaquine 
and artesunate, which cause extrapyramidal reactions, reporting on the whole 
remains low (22). 
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1.1.3.!WHO!Medicines!Regulatory!Harmonization!Mandate!
%
In 2008, the WHO estimated that only 20% of countries globally had efficient 
medicines regulatory bodies, with 30% of countries having very limited or no 
regulatory systems for health products. More than two-thirds of the world lives in 
areas with high disease burdens and where medicines are not regulated effectively 
(18). 
 
In 1975, the World Health Assembly (WHA) called on the WHO to be of greater 
assistance to member states regarding medicines regulatory systems. The WHO 
conducted studies in 1999, 2002, 2003, 2007 and 2010 pertaining to this. The 
2010 country profile pilot study for 12 countries, with varying disease burdens 
and regulatory capacity, was analysed and resulted in the conclusion that 
regulatory systems differ in funding systems, legal provision for clinical trials and 
pharmacovigilance, as well as Good Distribution Practice (23). 
 
The WHO has an international mandate to support member countries in 
improving public health globally (24). This has also involved providing support 
for improving medicine regulation in developing countries through training and 
capacity building as well as the development of regulatory procedures and 
guidelines. This has also involved support through the WHO Certification Scheme 
and quality control laboratories, as well as the WHO Medicines Prequalification 
Programme (1).  
 
The WHO Certification Scheme is an international agreement that provides 
assurance of the quality of a finished pharmaceutical product. It allows member 
states to issues Certificates of Pharmaceutical Product to confirm that a product 
has received market authorisation in a country and has been manufactured 
according to GMP (25). This is useful for developing countries that wish to export 
their products to other countries to prove compliance with WHO regulations. 
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The WHO Medicines Prequalification Programme has been effective in increasing 
capacity of regulatory authorities for GMP inspections through training of 
inspectors. It also provides a list of products that meet current GMP standards, 
while still encouraging autonomy of regulatory authorities with regards to 
assessment for market authorisation and post-marketing surveillance. However, 
the prequalification programme has been criticized as allowing lower standards 
than those of more stringent regulatory authorities as well as that required by the 
International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) (26).  
 
The Prequalification Programme is more focused on generic medicines, while the 
ICH guidelines are focused on New Chemical Entities (NCEs). WHO 
prequalification standards are applied to essential medicines, and therefore play a 
priority role in Africa, where the majority of medicines used are primarily generic 
products. It has been found that the ICH harmonization process is a costly and 
time-consuming exercise, which has involved stakeholder commitment and 
funding to reach its current status. ICH guidelines are applicable to NCEs, rather 
than generic products that are more common in the developing world (26). 
 
The fact that the developing world may find the WHO standards more viable and 
that the perceived gap in quality of the WHO and ICH standards may affect 
willingness of regulatory authorities to harmonize, especially with regards to 
generic medicines requirements. The ability and willingness of regulatory 
authorities in SADC to comply with harmonization standards was also the subject 
of this study. 
 
The WHO has also chaired the International Conference of Drug Regulatory 
Authorities (ICDRA) since 1980, which provides an ideal platform for networking 
and communication between WHO member states on regulatory activities and 
advances (24).  
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A study was conducted by the WHO between 2002 and 2009 to assess the state of 
medicine regulation in 26 countries in sub-Saharan Africa. This study found that 
regulatory authorities in most countries were financially and human resource 
constrained. It also found that there was a lack of autonomy and almost no ability 
of the regulatory authorities in developing countries to evaluate innovator 
applications, as these require a more complex review process than with generic 
applications. A total of 92% of the countries noted that a lack of qualified experts 
to evaluate the regulatory dossiers inhibited the efficiency of the regulatory 
authority. These findings were summarised in the FIGURE I below, from the 
WHO report (27). 
 
FIGURE I: Resources for Medicines Registration (27) 
!
!
Conclusions drawn from the study to address the constraints listed involved 
increasing political will and to increase capacity of regulatory authorities through 
harmonization, training and other support from the WHO and other regulatory 
authorities (27). 
 
 
% !
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1.1.4.! Harmonization! in! the! European! Union! (EU)! and! the!
International!Conference!on!Harmonization!(ICH)!
%
Events such as the Tuskegee tragedy, involving the injection of African-American 
patients with syphilis for the purpose of conducting clinical trials, led to the 
implementation of clinical research policies and legislation worldwide, including 
the Nuremberg Code in 1947 and the Declaration of Helsinki in 1964 (28). There 
also emerged the realisation of the need for medicines regulation to avoid events 
such as the Thalidomide tragedy in the 1950s and 1960s, involving severe 
malformations in thousands of babies born to mothers who had consumed the 
medicine to treat nausea (29). 
 
A framework of minimizing duplication of medicines regulatory activities and 
clinical trials was needed, as well as to reduce the need for animal testing (28). 
This led to a valuable initiative to promote effective harmonization of medicines 
regulation with the creation of the ICH in 1990. This tripartite alliance of Europe, 
Japan and the United States was successful in avoiding duplication of registration 
requirements (3).  
 
The Common Technical Document (CTD) format was developed to improve 
efficiency by reducing costs and maximizing human resources by reducing time to 
reformat registration dossiers for medicines. The CTD is a common, 
harmonization application format that consists of five modules – Module 1 is 
specific to local requirements of regulatory authorities, while Module 2 to 5 are 
common to all applications (30). The CTD format was finalised in November 
2000 and has since been adopted by the ICH countries as well as many countries 
outside of the ICH (31). The CTD format also helps to bring products to the 
market in multiple countries more efficiently, using a “common regulatory 
language”. This is significantly important in low-income countries, with a lack of 
expert resources (3). 
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In addition to the ICH framework for regulatory harmonization, there is mutual 
recognition that exists between the country regulatory bodies within the EU, 
including a centralised registration procedure, which enables diversification of 
skills of the participating regulatory authorities as well as opportunities for 
learning outside of a country’s borders (24). The centralised procedure came into 
effect in 1995, where applications are sent directly to the EMA for review. The 
applications are then assessed by the Committee for Medicinal Products for 
Human Use or Committee for Medicinal Products for Veterinary Use, as 
applicable. Once the committee approves the registration of a product, the 
registration is valid in all EU member states for five years (32). 
 
Other methods of registration are possible in the EU, such as mutual recognition, 
where a product may be registered in one country and then on subsequent 
application to other countries in the EU, under this procedure, regulatory 
authorities do not undertake full evaluation of the application, but use the 
regulatory decision made by the first country. For products outside of the EMA’s 
scope, applications may be sought from each regulatory authority simultaneously 
(33). This is a system to which other Regional Economic Communities, including 
SADC, may benefit from.  
 
As a further means for supporting regulatory decisions in developing countries, 
the EMA works with the WHO to form a scientific opinion of products that “are 
intended exclusively for markets outside of the European Union”. These 
medicines used for public health benefit to treat diseases not highly endemic to 
the EU including treatment for HIV, malaria and TB, as well as vaccines for 
WHO priority diseases. The products on which an opinion is formed are not 
registered for use in the EU, but an opinion is sent to the WHO and non-EU 
regulators to enable regulatory decision (34). 
 
However, the wider adoption of the CTD/eCTD format within the EU region 
remains limited and many countries continue to use older application formats (35). 
Page%|%11%%
%
The EMA and FDA have a cooperative agreement, which includes information 
sharing of pharmacovigilance data, paediatric studies and audit reports (36). 
 
Currently, the majority of the regulatory authorities in the world, mostly in 
emerging economies, do not belong to ICH, although many now have observer 
status. These countries find that the WHO standards are more viable to implement 
than ICH, which many have suggested are more costly and require greater human 
resource and technical capacity to implement. The WHO prequalification 
standards have been viewed by some as less stringent than the ICH standards (26). 
For example, ICH guidelines for stability testing require three batches of product 
to be tested, while the WHO guidelines require only two (37). 
 
In a study conducted by Specht and Klingmann in 2014, 30 subjects from the 
European pharmaceutical industry and regulatory authorities were interviewed to 
discuss successes and failures of the ICH. In the study, concerns were expressed 
that regulatory authorities in developing countries may not have the financial and 
human resources needed to contribute to the work of the ICH and conform to its 
standards (38). Several participants in the study conducted by Specht and 
Klingmann expressed concerns that ICH guidelines need improvement and that 
implementation should be enforced in a stricter and more efficient way. The need 
for better cooperation among regulatory authorities was also highlighted by the 
study (38). 
 
1.1.5.!Regional!Regulatory!Harmonization!Efforts!
1.1.5.1. Association of Southeast Asian Nations (ASEAN) Region  
 
The Association of Southeast Asian Nations (ASEAN) Region consists of 10 
member countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, 
Philippines, Singapore, Thailand and Vietnam) (24). This was the first region to 
introduce limited harmonization of regulatory functions and activities in 1967 to 
increase pharmaceutical trade, with a focus on mutual recognition of GMP 
standards and inspections (20). The region consists mainly of middle to lower 
Page%|%12%%
%
income countries, with many challenges to healthcare in the region including a 
neglected tropical disease burden, TB, avian influenza, as well as non-
communicable diseases (39). 
 
To address the burden of diseases specific to the region, these countries developed 
the ASEAN Network for Drugs, Diagnostics, Vaccines, and Traditional 
Medicines Innovation (ASEAN-NDI) in 2009, aimed at promoting research and 
development of pharmaceuticals to treat priority diseases in the area (40). The 
ASEAN Sectoral Mutual Recognition Arrangement for GMP for Manufacturers 
of Medicinal Plants, recognising GMP certificates and inspection reports, was 
signed in 2009 in an effort to avoid duplication of efforts. The ASEAN Common 
Technical Dossiers and ASEAN Common Technical Requirements have been 
developed to ensure harmonized quality, safety and efficacy requirements for 
applications for registration in the region (41).  
 
1.1.5.2. Asia-Pacific Economic Cooperation (APEC) 
 
The Asia-Pacific Economic Cooperation (APEC) was created in 1989 consisting 
of 21 countries, including Australia, China, Hong Kong, Canada, Japan, USA and 
many regulatory authorities that also belong to other regulatory harmonization 
initiatives in the Pacific Rim (24). The APEC Harmonization Centre (AHC) was 
developed in 2009, aimed at harmonization of regulatory requirements for 
medicines and medical devices in the region (42). 
 
Although medicines harmonization activities in the region were only recently 
established, much progress has been made to date in developing harmonization 
review processes. The region has developed a “2020 Good Review Practices 
Roadmap” to coordinate harmonization of medicines regulatory requirements in 
the region. A number of workshops have been held to agree on the basics of the 
review process and to promote best practices, including one in 2014 with 133 
representatives from 20 countries in the region (43). 
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1.1.5.3. Gulf Cooperation Council (GCC)  
 
The Gulf Cooperation Council (GCC) was created in 1981 and consists of 6 Arab 
states (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates). 
The Gulf Central Committee for Drug Registration coordinates policies and 
information sharing, including with GMP inspections (24). 
 
The GCC established a centralised review procedure for NCEs and generic 
medicines using a GCC Central Drug Registration Committee in 1999. The 
process for review involves two authorities assessing the application for 
registration with the other countries being provided with copies of the application 
(44). 
 
However, there have been concerns from the pharmaceutical industry that 
harmonization initiatives in the region are increasing medicine registration times. 
A study conducted by M.H Al-Rubaie et al in 2013, involving 413 products that 
were reviewed by the GCC centralised review process, found that the mean time 
taken to review applications had increased from 2006 to 2010, and was attributed 
to time-consuming centralised review processes (45). 
 
1.1.5.4. Pan American Health Organization (PAHO) 
 
The Pan American Health Organization (PAHO), together with the WHO, created 
the Pan American Network for Drug Regulatory Harmonization (PANDRH) in 
1999. This has focused on training and the establishment of common technical 
guidelines on GMP, pharmacovigilance and other regulatory activities within the 
region (24). 
 
The PANDRH began working with regulatory authorities in the region in 2000 to 
build capacity, including in the areas of licensing of manufacturers, product 
quality, safety and reducing counterfeit medicines. This has involved establishing 
a network of laboratories and pharmacovigilance activities, as well as registration 
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activities. The regulatory authorities of Argentina, Brazil, Canada, Colombia, 
Cuba, Mexico and the United States were designated as models for regulatory 
excellence for other countries in the region (46). 
 
The PANDRH holds regular conferences to discuss regulatory harmonization in 
the Pan American region and systems to overcome challenges in the area. In 
September 2013, the seventh PANDRH meeting was held in Ottawa, Canada, 
with a focus on pharmacovigilance, medicines regulatory harmonization 
promotion and the development of mechanisms for regulatory training. This 
meeting acknowledged the need for improvement in the area of regulatory 
sciences and countries were given the mandate to develop regulatory capacity 
through “competency-based” curricula at training institutions (47).  
 
1.1.5.5. African Medicines Regulatory Harmonization (AMRH) Initiative  
%
The International Conference of the Drug Regulatory Authorities (ICDRA) is a 
forum for regulatory authorities to discuss challenges in medicines regulatory 
affairs worldwide, as well as to discuss solutions. It is a meeting of global 
regulatory authorities to exchange ideas and collaborate on initiatives, including 
regulatory convergence and harmonization (48). 
 
At the 13th ICDRA meeting in 2008, consisting of more than one hundred United 
Nations (UN) member countries, concerns were raised about the need for 
harmonization in many regions of the world and particularly in Africa. This 
resulted in the AMRH Initiative being established (49). The initiative divided 
African countries into 5 regional groups, with a 5-year project plan. Of these, the 
Economic Community of Central African States (ECCAS), SADC and EAC are 
the most advanced to date (36). 
 
An African Regulatory Conference was held in Johannesburg in 2010 to further 
these objectives and was attended by regulators from forty countries in Africa. 
Here, the WHO reiterated that shared knowledge of product assessment would 
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improve harmonization by minimising repetition of work efforts and thus improve 
quality of public healthcare (36). The WHO, amongst others, provides support to 
developing countries in establishing common technical and administrative 
requirements such as the use of the CTD format for submission of registration 
applications and ICH standards, as well as encouraging collaboration with the 
inspections of manufacturing facilities. The activities of the AMRH Initiative to 
assist with regional harmonization on the continent are also supported by the Bill 
& Melinda Gates Foundation and the World Bank (49). 
 
The AMRH Initiative is a technical unit of the African Union (AU), responsible 
for facilitating and implementing regional initiatives and encouraging 
communication between stakeholders. The AMRH Initiative’s main strategic 
areas of focus include policy and regulatory framework harmonization, capacity 
development, improving communication and an enabling environment for 
regulatory harmonization through monitoring systems, as well as sufficient 
control and networks for sharing of knowledge (50). The AMRH Initiative aims to 
enable countries to move towards achieving their Millennium Development Goals 
(51). 
 
It has been noted by the AMRH Initiative that accountability by member states is 
important to ensure optimal coordination of harmonization activities. Priority 
areas such as regulation of medicines should be attended to before focusing on 
other regulatory functions. Registration may be used as a pilot to establish how 
other functions may be addressed (50). Sovereignty of the countries is imperative 
in this process. Critical milestones for regulatory harmonization were proposed by 
the AMRH Initiative (52), which were adapted in TABLE I below. 
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TABLE I: Critical Milestones for Regulatory Harmonization 
Level of Harmonization 
Independent  Regulatory 
Convergence 
Harmonized 
Standards 
Centralized 
Regulation 
Each authority 
has its own 
standards  
Information 
Sharing 
Joint evaluations 
and inspections 
Registration on 
behalf of 
participating 
authorities 
Own specific 
requirements for 
registration  
Harmonization 
GMP Guidelines 
Mutual 
recognition of 
decisions 
 
 Harmonized 
registration 
requirements 
Quality 
Management 
Systems 
 
  Management 
Information 
Systems 
 
Adapted from African Medicines Harmonization Initiative (52) 
 
1.1.5.6. East African Community (EAC)  
 
The first successful regional group of the AMRH Initiative has been that of the 
EAC Medicines Registration Harmonization project, which was started in March 
2012 and involves Uganda, Kenya, Tanzania, Rwanda and Burundi (49). The 
project involves a combined effort in the assessment and approval of medicine 
registration applications, as well as common standards for manufacturing facilities 
(according to GMP and Quality Management Systems) and technical 
requirements. The EAC has since become a member of the ICH Global 
Cooperation Group, attending meetings and being exposed to knowledge sharing 
with other regulatory harmonization initiatives such as the APEC Regulatory 
Harmonization Initiative (36). 
 
Support from the World Bank with regards to funding and expertise has been a 
major contributor to the EAC’s successes in harmonization. The World Bank has 
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recently agreed to provide similar funding to SADC. However, the difference with 
the EAC and SADC is also suggested as being due to the similarities in regulatory 
capacity of the EAC countries. Within SADC, country capacity varies greatly 
from Zimbabwe and South Africa who are seen as having relatively well-
developed regulatory bodies to Swaziland with a very poorly developed 
regulatory authority, consisting of only two evaluators.   
 
The EAC has a mandate to facilitate regional cooperation including in health, 
through enabling regulatory harmonization. A great deal of consultation between 
regulators, industry and policy-makers has enabled the establishment of a 
governance structure, with a project steering committee and technical working 
groups (50). The EAC has made significant progress towards harmonization of 
regulatory requirements, including producing regulatory tools and guidelines, 
organizing joint inspections along with the WHO as well as building harmonized 
information systems (53). 
 
Endorsement from stakeholders is a key area of implementation that has been 
identified by the EAC. The success of regional initiatives will establish a 
foundation for a single African medicines regulatory body. Cooperation, 
commitment and collaboration by all stakeholders are key (50). 
 
1.1.5.7. Southern African Development Community (SADC) 
 
Many consider the origins of SADC, originally the Southern African 
Development Coordination Conference (SADCC), to have been from the 
“political alliance” of countries in Southern Africa in fighting against white 
oppression in the 1970s (54). SADCC was established in 1980 to improve 
economic development in the region, with each country being responsible for a 
different sector within the region. The organization has historically provided poor 
communication and a lack of cohesion between member states, and economic 
instability has led to an over-reliance on donor funding in most of the region (55). 
The SADC region currently consists of fifteen countries, including 
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Angola, Botswana, Democratic Republic of Congo, Lesotho, Madagascar, 
Malawi, Mauritius, Mozambique, Namibia, Seychelles, South Africa, Swaziland, 
Tanzania, Zambia and Zimbabwe (56). 
 
The SADC Health Protocol for Regional Cooperation and Integration has been in 
existence since 1999 and forms the basis of regional health governance and 
collaboration (24). The SADC Protocol on Health provides a framework for 
cooperation and integration of health policies to alleviate the burden of diseases 
prevalent in the area, such as HIV, TB and malaria. The protocol provides 
strategies, including regulatory integration, to achieve the goal of “Health for All” 
in the member countries by 2020 (49). SADC developed a Health Policy 
Framework, which was approved in 2000. This focused on “health research and 
surveillance, health information systems, health promotion and education, HIV 
and AIDS and sexually transmitted diseases, communicable and non-
communicable disease control, disabilities, reproductive health, health human 
resources development, nutrition and food safety, and violence and substance 
abuse” (57). 
 
However, a satisfactory level of harmonization of regulatory activities has not yet 
been achieved in the SADC region. Potential barriers to harmonization may relate 
to differences in the organizational structure of regulatory authorities within the 
region, differing legislative and regulatory provisions as well as different levels of 
technical capacity for regulation among member countries (24). 
 
Whilst the literature appears to be sparse with regards to assessments of regulatory 
harmonization in Africa and the SADC region in particular, a study conducted by 
Narsai et al in 2012, involving 33 members of pharmaceutical companies in South 
Africa with a presence in other SADC countries, investigated obstacles to 
regulatory harmonization within the SADC region. This study revealed that 
barriers to availability and accessibility of quality, safe and efficacious medicines 
to the markets within the SADC region were mainly due to resource limitations. 
Pharmaceutical companies interviewed stated that they were reluctant to export 
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their products to certain countries within the region due to different requirements 
and costs such as for registration, retention and inspection. 82% of pharmaceutical 
company representatives that participated in the study were in favour of 
harmonization of legislative frameworks for medicine regulation (58).  
 
The study recommended that the SADC region harmonize legislation 
requirements as soon as possible, which will benefit pharmaceutical industry, 
patient groups and healthcare professionals. It also recommended evaluating 
regulatory requirements to assess essential requirements, in an effort to reduce the 
time taken for the registration of products (58). 
 
1.1.5.8. Zazibona 
 
Frustrated with the time delay in SADC harmonization attempts, the regulatory 
authorities from Zambia, Zimbabwe, Botswana and Namibia embarked on an 
initiative to pilot harmonization in the region. This collaboration was termed 
“Zazibona” and has resulted in the successful registration of a number of 
products, as well as reduced the average of 24 months’ registration time to 9 
months. The initiative focuses on registration of products for ten priority diseases 
in the region, including TB, HIV and malaria (59). The four countries have also 
undertaken joint inspections, where manufacturing facilities have been inspected 
for GMP compliance (60). Other member states in the region such as South Africa 
have also been invited to participate in this pilot initiative.   
!
1.1.6.!World!Bank!Agreement!
 
The World Bank has provided funding for the EAC harmonization initiative since 
2011 (61) and initially rejected the proposal sent by SADC, but has recently 
agreed to fund the SADC regulatory harmonization initiative with a 5-year 
duration. 
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The goals of the initiative are to “improve the availability of medicines through 
the regional harmonization of regulatory systems, guidelines and processes among 
Member States in the SADC through:  
• Harmonizing the system of medicines registration and broadening the scope of 
products reviewed (NCEs, vaccines and biologicals) and regulatory functions 
undertaken (clinical trial oversight, pharmacovigilance etc.), 
• Achieving political, legislative and financial support by communicating the 
value of the project to all stakeholders,  
• Building regulatory capacity and capability, and  
• Sharing information to facilitate faster decision making” (62). 
 
Another key goal of the initiative is to “develop and implement national and 
regional management information systems”. This will address the barrier of lack 
of information sharing and transparency by creating such a platform. Creation of a 
Quality Management System and Monitoring and Evaluation System are key 
goals that, if implemented, will enable implementation and monitoring of 
adherence to guidelines and procedures, ensuring optimal performance (62). 
 
1.1.7.!The!Need!for!Global!Regulation!
%
The increasing globalisation and decentralisation of the pharmaceutical industry 
affects regulatory issues worldwide. The United States of America currently 
imports 80% of its active pharmaceutical ingredients for pharmaceuticals and the 
FDA regulates products manufactured at about 300 000 manufacturing sites in the 
world. Many of these sites are located in countries with regulatory systems 
viewed as “weak” by the FDA, including India and China (12).  
 
A weak regulatory system in one country may have a substantial impact on many 
others, if the country produces active ingredients, other excipients or products for 
other countries. Although the FDA is seen as a “stringent” regulatory authority, it 
has recognised that the quality of the pharmaceutical products in the United States 
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is impacted by less developed regulatory authorities (63). The FDA has therefore 
identified a need for harmonization on a global scale (12).  
 
Although regional harmonization efforts have proved relatively successful in 
some cases, a global regulatory framework to encourage a sustainable approach to 
addressing these issues may be needed. This would result in a more coordinated 
framework for capacity building, improved transparency and overall quality of 
pharmaceuticals. Global regulation in other industries has shown that without 
accountability, individuals and organization lack the sense of urgency and 
commitment to adhere to rules and regulations (12). 
 
The Council on Foreign Relations, an independent advocacy organisation in the 
United States, indicated in September 2013 that “success of global regulatory 
schemes developed in other sectors appears to be contingent on five distinct 
stages: agenda setting, negotiation, implementation, monitoring, and 
enforcement”. A multi-sectoral approach, including all stakeholders in medicines 
regulation such as the non-profit, academic, private and government sectors, is 
necessary to ensure sustainability and cooperation. The strengths and resources 
that each sector brings in medicines regulatory affairs will enable an increase of 
capacity and communication. This in turn will lead to greater trust in the 
regulatory system (12). 
 
With the rising costs of medicines development, a collaborative public-private 
approach on a global level for medicines regulation is imperative. An example of 
a functional global harmonization standard is the use of bankcards to enable 
currency withdrawal from most ATM machines throughout the world. In order to 
ensure successful implementation, standards should be able to be enforced by 
regulators. A key method to enable this is the inclusion of provisions in health 
product legislation that allows the regulator to adequately enforce penalties if 
standards are not upheld. 
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Harmonization of medicines regulatory activities encourages sharing of 
information and technology, and promotes better access to medicines (1). The 
available literature supports the view that harmonization would be beneficial to all 
parties in a healthcare system. It consists of synchronization of scientific 
requirements for regulatory applications, leading to acknowledgement of 
scientific data, as well as synchronization of format and procedures for review 
that aids evaluation and approval (35). 
 
The literature also suggests that on harmonization supports capacity building of 
medicines regulatory authorities through utilization of expertise from other 
countries, as well as improved public perception. Pharmaceutical companies 
would also increase profitability by globalization. Patients would gain better 
access to effective pharmaceuticals, also reducing costs incurred to them and the 
healthcare system of the country (58). However, barriers exist to achieving this 
goal, which were explored in this study.   
 
1.2.!Problem!Statement!
%
The current lack of regulatory harmonization in the SADC region significantly 
undermines the availability of safe, effective and quality essential medicines in the 
region. Harmonization of regulatory requirements and procedures within the 
region would lead to a more efficient environment for market access, as well as to 
allow wider distribution of essential medicines in the region. There is clearly a 
need to assess potential barriers to harmonization within the SADC region and 
identify possible strategies to address these.  
 
1.3.!Study!Aim!
The aim of the present study is to identify the perceived barriers to current 
medicines regulatory harmonization efforts within the SADC region by 
stakeholders involved, as well as possible strategies to address the barriers. 
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1.4.!Study!Objectives!
The objectives of the study are the following: 
• To evaluate the current status of medicines regulatory harmonization 
within the SADC region; 
• To identify and explore the perceived barriers to medicines regulatory 
harmonization of the national regulatory authorities within the SADC 
region; 
• To identify possible strategies and recommendations to address the 
recognised barriers to regulatory harmonization within the SADC region. 
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Chapter!2!–!Methods!
A cross-sectional exploratory study design with qualitative techniques, as well as 
an inductive-deductive approach, which involved the prior identification of 
emergent themes as well as the emergence of new themes, was used. In-depth 
face-to-face interviews with key informants from various stakeholders in the 
healthcare sector, involving secondary formal qualitative approaches to identify 
the emergent themes, was utilised initially. This was deemed beneficial in this 
context, as it assisted in formulating the retrospective hypothesis of existing 
barriers to medicines harmonization, used later in the cross-sectional study. A 
study sample consisting of regulatory authorities in the SADC region was used in 
the cross-sectional study.  
 
2.1.!FaceXtoXFace!Interviews!
 
Initially, a series of semi-structured, one-on-one interviews with 4 key 
interviewees from the SADC Secretariat, the African Medicines Harmonization 
(AMRH) Initiative and the Southern Africa Regional Programme on Access to 
Medicines and Diagnostics (SARPAM) was used. The sample used for this was 
purposive, as senior policy specialists and decision-makers from the relevant 
institutions were targeted. Inclusion criteria for interviews were key decision 
makers who had a sound knowledge of medicines regulatory harmonization 
activities. The number of interviewees was tailored according to the point that 
data saturation was reached. This occurred when a theme was repeated three to 
four times and no new codes were formed. Standardized, open-ended questions 
were used to allow ease of comparison and replication with interviewees. 
 
The following were adhered to during the face-to-face interview: 
• A setting with minimal distraction was identified; 
• The purpose of the study was explained and queries addressed; 
• The format of the interview and expected duration were explained; 
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• Contact information was provided and consent obtained, as well as 
explanation that names would be kept confidential, but that geographical 
location and role in organization may be stated in results. 
 
Biased questioning was avoided and participants were encouraged to lead the 
interview, defining the content. Controversial questions were left until the end of 
the interview and factual questions were asked first. At the end of the interview, 
points reported were summarized and accuracy confirmed with the participant. A 
neutral, unbiased person with no link to the participants assessed electronic 
records of interviews conducted. If any bias was suspected, participants could be 
contacted to ensure objectivity and reconfirm their view. However, this was not 
necessary, as the interviews were considered to be unbiased.  
 
2.2.!Piloting!of!the!Questionnaire!
%
A questionnaire was formulated and adapted using secondary data collected from 
the face-to-face interviews. Themes derived from the interviews were challenged 
or confirmed by responses to this questionnaire.  The tool was piloted with a 
group of 6 individuals – 3 research experts who are regularly involved in the 
design of clinical research studies, 2 members of the Medicines Control Council 
(MCC), both of whom were regularly involved in harmonization initiatives, and 
one member of the AMRH Initiative to determine acceptability, validity and 
reliability of the method. The pilot sample used was chosen out of convenience 
and where face-to-face or telephonic contact was already established. The 
questionnaire was assessed for fluidity, ease of use, completeness of parameters 
used, ability to comprehend key issues, time taken to complete, fairness and lack 
of bias. 
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2.3.!Distribution!of!Questionnaire!
%
The questionnaire was designed before the face-to-face interviews, then adapted 
after the interviews to confirm themes derived from the interviews. The 
questionnaire was formulated in English, and data collected therefore had a bias 
towards English-speaking and educated individuals. However, as English is a 
requirement of all regulatory submissions in the SADC countries, it was assumed 
that the target population was proficient in English and would therefore respond. 
Questionnaires were delivered via email to the members of the relevant national 
medicines regulatory authorities. It was confirmed beforehand that the target 
population had sufficient Internet connectivity to support communication.  
 
Questionnaires were sent to senior members of all 15 regulatory authorities 
belonging to SADC, including registrars and deputy registrars. The individuals 
were contacted using information available on the authorities’ websites. If no 
response was received from the questionnaires within two weeks, reminder emails 
were sent, with further email follow-up made for two months. If no response was 
received after two months from submission of the questionnaire, it was assumed 
that the subject was unwilling to participate.  
 
2.4.!Justification!for!Method!Used!
 
A qualitative method was used to identify perceived barriers that exist to 
medicines regulatory harmonization in the SADC region. Theoretical and 
analytical codes were identified from repeated ideas, concepts or elements. Codes 
were grouped into concepts, and then into categories. Mixtures of pre-set and 
emergent codes were used. Pre-set codes were derived from the literature research 
conducted and emergent codes were formulated according to word repetitions and 
indigenous categories. 
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Unstructured, open-ended questions, as used in the study, provide a framework for 
response, as well as allow freedom of expression of the respondent in the 
investigation (64). Using content analysis to draw conclusions, a range of issues 
that were perceived as impeding regulatory harmonization and improved 
standards of regulatory control in the SADC region were determined.  
 
TABLE II: Methods and Objectives of the Study 
Objective Method 
To evaluate the current status of 
medicines regulatory harmonization 
within the SADC region; 
 
To identify and explore the perceived 
barriers to medicines regulatory 
harmonization of the regulatory 
authorities within the SADC region; 
 
To identify possible strategies and 
recommendations to address barriers 
to regulatory harmonization within the 
SADC region. 
 
Interviews conducted; 
 
Questionnaires formulated and piloted; 
 
Questionnaires evaluated and adjusted 
then sent out via email; 
 
Content analysis. 
 
 
2.5.!Data!Analysis! !
2.5.1.!Content!Analysis!
%
Content analysis was used, which is the “objective, systematic, and quantitative 
description of the manifest content of a communication”, converting written and 
verbal information into a quantifiable format (64). Text from open-ended and 
structured questions was inferred into thematic unit categories for interpretation. 
Trend analysis was conducted, involving an in-depth analysis of patterns. 
Saturation points were reached when no new codes were formed. As modest 
claims were hypothesized, the sample size was small. The sample size did not 
impact the outcome of the qualitative analysis, as this was determined on point of 
saturation. Trends were interpreted according to discrete categories and compared 
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according to country perspective. Levelling of responses according to personal 
expression was also undertaken.  
 
Saturation points were reached rapidly during the conduct of the study, with most 
participants alluding to the same thematic concepts of the barriers to SADC 
harmonization. Although only 47% of the regulatory authorities that were sent the 
survey responded, it was determined that saturation points had been reached and 
qualitative analysis was possible.  
!
2.5.2.!Data!Collection!and!Analysis!Process!
%
In summary, the data collection and analysis processes were as follows: 
• Interviews were conducted and information assessed; 
• Questionnaires were formulated and piloted to assess fluidity, ease of use, 
completeness of parameters used, ability to comprehend key issues, time 
taken to complete, fairness and lack of bias;  
• Questionnaires were evaluated and adjusted, then sent out via email;  
• Completed questionnaires were collected; 
• Content analysis and identifying relevant themes and trends with regards 
to barriers to harmonization were performed. 
 
2.6.!Ethics!
%
Approval to conduct the study was obtained from the University of the 
Witwatersrand Human Research Ethics Committee 20 April 2015. Written 
consent was received from participants in the interviews. Written consent was also 
received from participants in the questionnaire. Consent forms and interview 
transcripts can be made available on request. 
 
!
% !
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2.7.!Limitations!
%
A number of limitations were identified involving the collection of data for the 
research study. Although all regulatory authorities in the SADC region were 
approached to complete the survey, only 7 out of the 15 Authorities (47%) 
responded. Responses received were personal views and did not necessarily 
reflect the view of the regulatory authorities or organizations. It was found that 
countries participating in harmonization activities such as Zazibona were most 
responsive to the questionnaires, while participants from countries where English 
is not a first language were least responsive. 
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Chapter!3!X!Evaluation!of!the!Current!Status!of!
Medicines!Regulatory!Harmonization 
%
The current status of medicines regulatory harmonization in the SADC region was 
evaluated from the face-to-face interviews. Using a small but diverse group of 
individuals involved in regulatory harmonization, from the SADC Secretariat, the 
AMRH Initiative, SARPAM and members of regulatory authorities, a broad 
understanding of the current regulatory environment was developed. During the 
interviews, various concepts emerged repeatedly, regarding the barriers to 
harmonization. These points became saturated following the piloting and 
distribution of the questionnaires to the wider regulatory participants.  
 
A trend analysis undertaken from responses to questionnaires and interviews 
showed participants from the various countries within SADC identifying similar 
themes, regardless of capacity and years of operation of regulatory authorities, as 
well as whether the authorities had participated in regional harmonization 
activities. Although some participants from advanced regulatory authorities only 
indicated value in convergence rather than complete harmonization at this stage, 
which may be a more realistic view due to the different capacities of regulatory 
authorities, all participants were in favour of harmonization, if the identified 
barriers could be overcome. 
 
Interviewees suggested that regulatory harmonization in the SADC region was 
“initially… driven by the industry” (Interviewee 3, AMRH Initiative). It was 
deemed by the industry as easier to submit one registration application to various 
countries to ensure greater market access. One interviewee involved in SADC 
harmonization activities at its commencement explained that “for the industry, the 
earlier their products can come to the market the better and their products can only 
come to the market on being registered” (Interviewee 1, SARPAM). 
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Although criticism of the SADC secretariat existed, it was agreed that various 
advances had been made in the SADC region. A SADC participant stated that “the 
first [priority] was to develop minimum standards, so [it] developed guidelines for 
registration and control of medicines. It [is then] up to countries to adopt those 
guidelines” (Interviewee 2, SADC). According to the interviewee, there has been 
an agreement to adopt the CTD format by all Ministers of Health in the SADC 
region.  
 
SADC, with the help of SARPAM, also created a procurement platform - “a 
database where countries are sharing information… to see how countries are 
comparing the prices that they are buying at” (Interviewee 1, SARPAM). SADC 
and SARPAM are also currently developing a pooled mechanism of procuring 
medicines with the vision to combine the assessment and registration of quality 
medicines with pooled procurement in order to ensure access to more affordable, 
safe and good quality medicines.  The SADC interviewee indicated that the 
organization’s “aspirations [are] that the region should be able to produce some of 
the medicines and procure together and ensure these medicines undergo stringent 
regulatory analysis to ensure that they are safe” (Interviewee 2, SADC). 
 
The Zazibona initiative was viewed by participants from SADC, SARPAM and 
AMRH Initiative in the face-to-face interview as being a key first step to 
harmonization. The SADC interviewee stated that it “is up to [the countries 
participating in the Zazibona initiative… to share… their experiences and we can 
see how… we can accommodate [them] in a SADC-wide programme” 
(Interviewee 2, SADC). As one of the drivers of this initiative, a participant from 
the AMRH Initiative stated that “for the SADC region, we rely heavily on 
Zimbabwe. Zimbabwe regardless of the economic situation... has retained and 
maintained the same level of capacity and… has played a very good role in 
teaching other countries in the region” (Interviewee 3, AMRH Initiative).  
%
One interviewee who has been involved with the Zazibona initiative indicated that 
it incorporated the harmonization work of “the East African Community as [a] 
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reference guide for setting up… standards and [in] November/ December [2014] it 
was officially integrated as a SADC programme” (Interviewee 3, AMRH 
Initiative).  The interviewee went on to say “I totally think the EAC can be used 
[as a model for SADC harmonization], the reason being is the way that it is 
structured [in such a way that] takes into account the variations in capacity”%
(Interviewee 3, AMRH Initiative).   
 
The face-to-face interviews showed that the current status of regulatory 
harmonization in the SADC region is one in which many barriers exist that must 
be overcome. The study showed that there is buy-in from the stakeholders 
involved in medicines regulation within the countries in SADC, but that progress 
towards harmonization had been slow to date. The Zazibona initiative emerged as 
a well-supported and successful effort that should be replicated. These themes 
were discussed through the survey responses in Chapters 4 and 5. 
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Chapter!4!X!Perceived!Barriers!to!Medicines!Regulatory!
Harmonization!
 
A number of barriers to medicines regulatory harmonization in the SADC region 
emerged through the face-to-face interviews. Through the questionnaire responses 
that were received, several recurring themes that were identified during the face-
to-face interviews were confirmed and reached saturation point rapidly. The 
barriers that emerged in the questionnaire component of the study are summarised 
in TABLE III below and explained in detail in this chapter. Responses were 
tabulated for each theme that emerged from the questionnaires and were 
simplified for consistency and ease of reference. Completed questionnaire 
responses are presented in Appendix 3. 
 
TABLE III: Perceived Barriers to Medicines Regulatory Harmonization 
 
Themes 
 
Contributing Factors 
 
Governance and Leadership within SADC 
Inertia 
Lack of Coordination 
Lack of Prioritization 
 
Capacities of Regulatory Authorities 
Limited human resources 
Different levels of development 
Maturity of regulation 
Different levels of expertise  
 
Financial Resources  
Different socioeconomic status 
Lack of funds to take part in activities 
 
Political Will Lack of perceived benefit  
Intra-SADC Relationships 
Diverse cultures and language 
Different heritage, tradition and cultures 
 
Risk-Benefit Analysis Difference Each regulator has final decision, with different interpretation and priorities 
Legal Framework 
Lack of adoption of CTD Format  
Lack of enabling legislation  
Out-dated SADC framework 
Lack of faith in harmonization guidelines 
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4.1.!Governance!and!Leadership!within!the!SADC!Secretariat!
!!
4.1.1. Survey Responses 
TABLE IV: Barrier of Governance and Leadership 
Question Respondent 8 
Strategies to improve harmonization Building of capacity at the Secretariat 
 
Respondent 8 stated that a possible strategy to improve harmonization would be to 
build capacity of the SADC Secretariat. This implies that the lack of capacity of 
the SADC Secretariat to coordinated harmonization activities is a major barrier to 
SADC harmonization. 
%
4.1.2. Interview Responses 
This major theme that was identified as a barrier by some participants involved in 
harmonization is the apathy or “inertia” of the SADC secretariat due to “protocols 
and bureaucracy” (Interviewee 2, SARPAM), limiting the progress of the SADC 
harmonization agenda.  One interviewee indicated that the “lack of coordination 
method of the SADC Secretariat... has really hampered progress in the SADC 
region” (Interviewee 3, AMRH Initiative). 
 
Interviewees indicated that the SADC secretariat does not prioritise harmonization 
as a key function and role within the organisation. In the face-to face discussion 
with a member of the Secretariat, willingness was expressed to support 
harmonization activities amongst member states once positive results of such 
initiatives began to emerge. This approach to supporting harmonization was 
considered more appropriate since “whatever [SADC does is taken] through the 
process of adaptation and domestication and.. through the Ministerial Technical 
Committee discussion for them to agree” (Interviewee 2, SADC). Poor 
cooperation between the SADC Secretariat and governing bodies has been a 
contributing factor impeding harmonization. 
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4.1.3. Discussion 
It was evident from the face-to-face interviews and questionnaire responses that 
many countries had been waiting on the SADC Secretariat to create an 
environment for countries in the region to harmonize. It appears that many 
countries had become frustrated with the inefficiencies within the SADC 
secretariat with regards to enabling harmonization activities and using funds 
designated for harmonization activities efficiently. This is a great concern, as 
harmonization needs to be encouraged on a SADC level to ensure the 
participation of all countries. 
 
However, the SADC Secretariat did not see merit in initiating harmonization, as 
the red tape within the SADC structure would not allow for a quick turnaround of 
efforts. It envisioned a scenario where the countries themselves would initiate 
harmonization efforts on their own,  and later request the support of the secretariat 
to facilitate engagement with the wider community within the region. This could 
result in issues around funding for these efforts, as well as coordination.  
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4.2.!Capacities!of!Regulatory!Authorities!!
 
4.2.1. Survey Responses 
TABLE V: Capacity Barriers of Regulatory Authorities 
%
The four respondents listed in TABLE V above belong to regulatory authorities of 
varying capacities, consisting of between 20 to 200 evaluators and registration of 
143 to 552 medicines annually. However, the themes that emerged regarding 
problems encountered in harmonization attempts and major perceived barriers 
were similar. Differences and limitations in capacity were common barriers 
perceived by respondents, a major theme that reached saturation in the research 
report. Another respondent added that “harmonization can only be discussed with 
certain SADC countries due to the large gap between the implemented regulatory 
systems”. 
%
4.2.2. Interview Responses 
A recurring theme that emerged from the interviews, which was then tested and 
confirmed in the questionnaire during the survey conducted was that “different 
Question Respondent 7 Respondent 8 Respondent 9 Respondent 
10 
Problems 
encountered  
Gaps between 
regulatory 
systems  
- Different 
levels of 
capacity  
Wide variation 
of regulatory 
systems 
Major 
barriers  
Different 
levels of 
development 
and maturity  
Dependency 
on external 
technical and 
financial 
support  
Difference in 
capacity levels  
Capacity 
limitations  
Number of 
evaluators 
 
90 Internal  
110 External 
15 Internal  
50 External 
11 Internal 
9 External 
24 Internal 
0 External 
Drugs 
registered in 
2014 
526 Generics 
26 NCEs 
425 Total 370 Generics 
4 NCEs 
143 Total 
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levels of development” and “human resources” (Interviewee 2, SADC) were 
major barriers to harmonization.  Interviewees who had been part of Zazibona 
activities sited “Different levels of capacity at different regulatory authorities” as 
a major problem encountered and perceived barriers to harmonization, as well as 
different “maturity”.  
 
One interviewee stated that “infrastructure is not the same, legal issues and laws 
are different and even in terms of the human resources – most of the experts who 
are dealing with regulatory issues may not have what is acceptable in terms of 
standard of training at international level” (Interviewee 2, SADC). It was also 
noted that the SADC regulatory authorities “need to recognise… that they are at 
different levels” (Interviewee 1, SARPAM).  
 
4.2.3. Discussion 
At a regulatory harmonization workshop held in Washington DC in 2013, the gap 
between regulatory authority capacities in developed and developing countries 
was discussed. It was found that these gaps lead to the inability of countries with 
different capacity to develop at the same levels. It was also found that many 
harmonization initiatives fail due to a lack of enforced legislation and 
participation, and that although countries often adopt harmonization in theory, 
they lack the resources to perform. Without sufficient accountability, 
harmonization activities are therefore not implemented (50). 
 
It is important that within the SADC context, the different levels of development 
and maturity of the regulatory authorities is taken into account. For example, 
Respondent 7’s regulatory authority with 200 staff, registering 552 products 
annually would not necessarily be at the same level as Respondent 10’s regulatory 
authority, with 24 staff, registering 143 products. Although the two regulatory 
authorities may not be able to fully harmonize at this stage, there are many areas 
that they may converge on, which are discussed in Chapter 5. 
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4.3.!Financial!Resources!
%
4.3.1. Survey Responses 
TABLE VI: Financial Resources Barriers 
Question Respondent 9 
Problems encountered in 
harmonization initiatives 
Cost of undertaking the activities 
Major barriers to harmonization Funding for joint work 
Sources of funding Government 
Fees levied by the regulatory authority 
Industry 
Donors 
 
Respondent 9 indicated that the regulatory authority they represented received 
funding from many sources, including the government, fees levied by the 
regulatory authority, industry and donors. One would assume that receiving 
funding from a variety of sources would enable adequate funding for 
harmonization activities. However, the respondent viewed costs and lack of 
funding as being a major barrier to harmonization. 
 
4.3.2. Interview Responses 
Most participants in the study saw lack of financial resources as a major barrier to 
harmonization. One participant stated that countries “have a huge amount of 
challenges from infrastructure to human resources [and] financial resources” 
(Interviewee 3, AMRH Initiative) and that the “variation of the socioeconomic 
status and the capacity to regulate medicine [is] a big factor that [leads to] either 
success or failure of harmonization in the SADC region” (Interviewee 3, AMRH 
Initiative).  
 
4.3.3. Discussion 
Regulatory authorities who had undertaken harmonization of regulatory activities 
cited “cost of undertaking the activities” and funding as major problems 
encountered and barriers to harmonization. Funding for joint work initiatives was 
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seen as a major barrier, as some governments do not have the financial means to 
attend meetings relating to harmonization activities. The recently signed World 
Bank agreement, as outlined on Page 19 of this report, will hopefully address this 
constraint as countries would be able to have access to funding for joint work 
initiatives and meetings. 
 
Funding sources for participating National Regulatory Authorities (NRAs) 
differed between government, fees levied by the NRA, industry and donors. 
However, a common theme, independent of funding source, was that finances 
posed a major barrier to harmonization.   
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4.4.!Lack!of!Political!Will!!
%
4.4.1. Survey Responses 
TABLE VII: Barrier of Political Will 
Question Respondent 5 Respondent 6 Respondent 8 Respondent 
10 
Problems 
encountered in 
harmonization 
initiatives 
Differing 
Assessment 
standards and 
levels of 
expertise 
Trusting other 
authorities’ 
decisions 
- Slow progress 
Major barriers 
to 
harmonization 
National pride - Lack of 
understanding 
of 
harmonization 
benefits 
- 
Participation in 
training on 
harmonization 
guidelines 
Yes - WHO 
and SADC 
Yes - WHO 
and ICH 
Yes - WHO Yes  
Involvement in 
information 
sharing in 
SADC 
Yes - Zazibona 
 
N/A 
 
Yes - SADC 
Heads of 
Agencies 
forum 
Yes 
Benefit from 
SADC 
Harmonization 
Yes Yes Yes – quicker 
registration, 
information 
sharing and 
capacity 
Yes 
%
The four respondents listed in TABLE VII above all saw benefit in SADC 
regulatory harmonization, and had been involved in harmonization activities. 
However, a common theme that emerged as a barrier to harmonization was trust 
in harmonization activities and decisions made by other regulatory authorities, 
which has led to slow progress so far. 
%
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4.4.2. Interview Responses 
One view emerged that NRAs in some countries like “South Africa... are not 
willing to work with other countries – they feel like working with other countries 
is dragging them back...[but] once the new South African Health Products 
Regulatory Authority (SAHPRA) is operational, South Africa can start looking 
into beyond its territory” (Interviewee 3, AMRH Initiative). Political will was 
seen by participants as important because, as one participant stated, “the minute 
you have country leadership, it instils ownership and ensures sustainability” 
(Interviewee 3, AMRH Initiative). 
 
4.4.3. Discussion 
It was noted by some participants that although the SADC ministers had agreed to 
use  the CTD format and adopt the protocol on harmonization, some countries 
were more interested in harmonizing than others. There may be many factors 
influencing this, including limited resources and funding to be able to provide for 
staff to participate in these activities, as discussed previously. 
 
The perception that some countries have not shown interest in harmonization 
activities in the past may be due to the fact that these countries may only stand to 
gain a small amount of time saved through joint registration of medicines and 
other regulatory issues may take priority for under-resourced regulatory 
authorities. These countries may not want to neglect their own growth, especially 
in South Africa with the impending implementation of the new regulatory 
authority, SAHPRA. South Africa may choose to become an observer for 
initiatives such as Zazibona in order to provide expertise and build capacity as 
well as to learn from the process, while not deviating from current standards and 
practices to which the country adheres. 
 
!
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4.5.!Lack!of!IntraXSADC!Relationships!!
!
4.5.1. Survey Responses 
TABLE VIII: Barrier of Lack of Intra-SADC Relationships 
Question Respondent 4 Respondent 5 Respondent 6 Respondent 8 
Major barriers 
to 
harmonization 
Issues of 
sovereignty 
National pride Trust building  Language 
barriers  
Benefit from 
SADC 
Harmonization 
Yes - working 
sharing to 
expedite product 
registration  
Yes Yes Yes - 
information 
sharing and 
capacity for 
quicker 
registration  
Most to gain 
from 
harmonization 
Recognition of 
work done by 
other member 
states  
Reduce work in 
country  
Facilitate 
learning  
Improve on 
assessment 
standards and 
elimination of 
duplication of 
work 
Knowledge 
sharing and 
faster 
decision-
making, 
leading to 
diminished 
back-logs 
N/A 
 
The above table displays the responses of four questionnaire respondents, 
detailing barriers relating to a lack of national relationships between SADC states. 
While all four respondents saw benefit in SADC harmonization, including 
reducing their own regulatory workload and reducing backlogs, the respondents 
saw a lack of trust and national pride, as well as language barriers as contributing 
to barriers to harmonization. 
%
4.5.2. Interview Responses 
It was noted by one interviewee that the EAC was “colonised by the British and 
Germans… so they had a lot of similarities in terms of culture and language.. 
[which made it easier] for the countries to work together” (Interviewee 3, AMRH 
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Initiative). It was noted that in comparison, the SADC region consists of countries 
with diverse cultures and languages. 
 
4.5.3. Discussion 
Diverse cultures and language within the SADC region is potentially a major 
barrier to harmonization. Although the majority of the region uses English as their 
main official language, the Democratic Republic of Congo uses French, while 
Angola and Mozambique use Portuguese. This was seen as a difficult obstacle to 
overcome and may contribute to communication challenges in harmonization 
activities in some countries in the region.  
 
Countries within SADC who lack mutual recognition and trade relations are at 
greater risk of these barriers. These issues evolve from less regional collaboration 
as compared to the EAC, which has agreements set up to encourage cooperation. 
 
Another issue facing the SADC region and affecting intra-SADC relationships is 
the perceived low standard of governance and transparency in some countries. 
Cooperation and mutual recognition has been highlighted as a key factor for 
cohesion and growth in the region. South Africa contributes the highest Gross 
Domestic Product in the SADC region and, along with Zimbabwe, is viewed by 
some as the “political engine” within SADC, but also risks being viewed as taking 
control and imposing its view on other members of SADC (49). 
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4.6.!RiskXBenefit!Analysis!and!Law!Interpretation!Differences!!
%
4.6.1. Survey Responses 
TABLE IX: Barrier of Risk-Benefit Analysis Difference 
Question Respondent 7 Respondent 8 Respondent 10 
Problems 
encountered in 
harmonization 
initiatives 
Final decision still 
remains with each 
regulator 
- Variation in 
regulatory systems 
Major barriers to 
harmonization 
- Poorly established 
regulatory systems 
Levels of 
development and 
systems  
Countries 
decisions are 
recognized from  
PIC/s countries  
No others within 
SADC 
ICH Countries 
No others within 
SADC 
Zazibona countries 
Registration of 
products based on 
registration in 
other countries 
No No Yes 
%
Respondent 10, indicated as registering products based on decisions made through 
the Zazibona initiative, saw the different levels of development of regulatory 
systems as a barrier to harmonization. Respondent 7 and 8, who both stated that 
they had not taking decisions from other SADC countries and had not registered 
products based on any other country’s decision, partly due to the barrier of 
different regulatory systems, echoed this theme. 
 
4.6.2. Discussion 
Different risk-benefit decisions and interpretation of legislation may affect the 
way that regulators in the SADC region make regulatory and product approval 
decisions and may create a barrier to harmonization. For example, even the 
interpretation of the AU Model Law may be different according to local needs. 
One respondent involved in regulatory harmonization activities stated that a 
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barrier to harmonization was that “the final regulatory decision still remains with 
each specific regulator.”  
 
At a regulatory harmonization workshop held in Washington DC in 2013, it was 
found that even under the same legal and scientific frameworks, regulatory 
authorities of countries prioritise different areas of risks and benefits during 
medicine regulation (50). The priority needs of the local population and 
epidemiology within a particular country may influence a regulator’s decision to 
approve or reject a medicine based on its efficacy and side effect profile. An 
example that was presented at the above-mentioned workshop included the 
withdrawal of approval of Avastin for breast cancer by the FDA due to a high side 
effect profile and a low proof of efficacy. However, Avastin is available in other 
countries for this indication, raising concerns from the public and potentially 
reducing trust in the regulator’s decision. Regulators need to make risk-benefit 
decisions with “balance and perspective” (50). 
!
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4.7.!Different!Guidance!Documents!and!Legal!Frameworks!
%
4.7.1. Survey Responses 
TABLE X: Barrier of Different Guidance Documents and Legal Frameworks 
Question Respondent 4 Respondent 5 Respondent 7 Respondent 9 
Problems 
encountered in 
harmonization 
initiatives 
- Legislation 
differences 
SADC 
Guidelines is 
out-dated  
- 
Major barriers 
to 
harmonization 
Difference in 
the legal 
frameworks 
and 
application 
format  
Legislation 
differences 
- Different 
guidance 
documents 
Priority areas 
for 
harmonization 
Format of 
Applications 
- Format of 
Applications 
Format of 
Applications 
In what year 
was your 
legislation 
created 
1929 
(undergoing 
update) 
 
1965 
 
1965  
 
2013 
 
The respondents listed in TABLE X above indicated legislation that was created 
from as far back as 1929 to as recently as 2013, with a recurring theme that 
harmonized legislation should include that of format of applications. The four 
respondents saw major barriers being caused by differences in legislation and 
guidelines that needed updating.  
%
4.7.2. Discussion 
The New Partnership for Africa's Development (NEPAD) undertook an analysis 
on regulatory agencies in Africa and found that although most countries had laws 
to enable regulation of medicines, most of these were out-dated and not 
comprehensive enough (62). This theme was repeated in the research study, in 
which participating countries’ medicine legislation dated as far back as 1929, 
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although this legislation is currently undergoing an update. All participating 
countries indicated that their legislation makes provision for the establishments of 
a NRA, which has the power to carry out inspections of pharmaceutical products 
and practices as well as the responsibility to deal with non-compliant products or 
companies.  
 
 To address this, the AU Model Law was developed to create a foundation on 
which regulatory authorities could build their legislation. This law was approved 
by AU Ministers of Health and is aimed at addressing issues that enable 
harmonization, including allowing information sharing and recognition of 
decisions by other regulatory authorities (65). 
 
The NEPAD situational analysis was confirmed by the findings in this study, 
where most respondents indicated that their legal frameworks currently do not 
allow for information sharing or harmonization in the SADC region. This would 
be a major factor that requires change if harmonization in the SADC region is to 
occur.  
 
The use of different guidance documents and legal frameworks was seen as a 
major barrier to harmonization. This includes the fact that although the Ministries 
of Health within SADC have agreed to adopt the CTD format, not all countries 
within SADC have implemented the format completely. This difference in format 
is a major barrier, as pharmaceutical companies are forced to submit different 
formats to different countries and joint evaluation is extremely difficult. 
 
An on-going challenge is the ability to adapt requirements to each country’s 
environment. This is a major barrier which must be resolved as lack of faith in the 
SADC guidelines could lead to countries becoming resistant to adopting them, 
leading to a lack of harmonization. For example, another respondent who cited 
that the guidelines were out-dated added that WHO guidelines addressing 
harmonization were used instead of the SADC guidelines. A lack of faith in the 
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guidelines is a major issue as, without adoption of these guidelines as a 
foundation, harmonization in the region will be almost impossible. 
 
% !
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Chapter!5!X!Possible!Strategies!and!Recommendations!
to!Address!Barriers!
%
A number of possible strategies to address identified barriers to medicines 
regulatory harmonization emerged in the face-to-face interviews, as well as the 
questionnaire responses. These are summarised in TABLE XI below and 
explained in this chapter. Questionnaire responses were tabulated for each theme 
that emerged and were simplified for consistency and ease of reference. Complete 
questionnaire responses are presented in Appendix 3. 
TABLE XI: Strategies and Recommendations to Address Barriers 
 
Themes 
 
Contributing Factors 
 
EAC and Zazibona as Models 
Reference guide for standards 
Variations in capacity of regulators 
Tanzania experience 
 
Format Harmonization (CTD) and 
Model Law Adoption 
Information sharing and transparency 
Cooperation 
Market access for industry 
Easier work sharing initiatives 
 
Redirect Focus 
Scientific and technical matters over 
legislation 
Prioritise information and work-sharing  
 
Regulatory Initiatives 
Power of decision making 
Coordinate outside of SADC secretariat 
 
World Bank Agreement 
Funding for harmonization 
SADC harmonization goals 
 
Capacity Development 
Centres of Regulatory Excellence 
Harmonized Curricula 
 
Convergence over Harmonization 
API and Biowaiver requirements 
Post-registration amendments 
International Generic Drug Regulators Pilot 
 
Global Regulation 
Globalisation of industry 
Capacity building and transparency 
 
%
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5.1.!EAC!and!Zazibona!as!Models!
%
5.1.1. Survey Responses 
TABLE XII: Strategy using EAC and Zazibona 
Question Respondent 4 Respondent 8 Respondent 10 
Strategies to 
improve 
harmonization 
Work-sharing such 
as Zazibona 
Joint assessments 
and inspections as 
pilot projects  
Moving with a 
subset of countries 
that have similar 
systems 
Perceptions of the 
Zazibona initiative 
Great initiative to 
speed up market 
authorization, 
minimization 
duplication and 
allow learning  
Stringent regulatory 
requirements and 
information 
sharing, providing 
capacity building 
and reducing 
workload 
Reduction of 
substandard 
medicines 
Allows sharing of 
information and 
collaboration – full 
participation 
 
Various respondents, including three respondents listed in the table above, saw 
work-sharing and joint assessments through collaboration efforts such as the 
Zazibona initiative as good strategies to improve harmonization. One respondent 
in the Zazibona initiative described it as a “good way of sharing work, trust 
building and capacity building” and that continued participation would result in 
“continued capacity building and work sharing. It would also lead to recognition 
of work by other countries including report sharing and decisions.” Another 
respondent indicated that the initiative addressed one of the barriers to SADC 
harmonization, in that strict regulatory standards were upheld and capacity was 
improved through training aimed at regulators with a lower level of capacity.  
Even respondents that were not, at the time of the study, part of the Zazibona 
initiative expressed support and indicated the value that they saw in all SADC 
member states being part of the initiative. 
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5.1.2. Interview Responses 
The interviewee from the AMRH Initiative stated that lessons might be taken 
from the success of the EAC, in that, with the will of member states, 
harmonization will be possible. The AMRH Initiative respondent indicated that 
the organization would like to use the EAC model for implementation in the wider 
African community and that, although each region comes with a different set of 
challenges, the basic framework for harmonization used in the EAC may be 
replicated.  
 
Another interviewee indicated that “the EAC has done a lot in terms of putting the 
structures that will drive the process” (Interviewee 1, SARPAM) and also 
indicated that SADC, although more advanced in implementing the CTD format, 
would be able to model their harmonization efforts on the EAC. 
 
5.1.3. Discussion 
Countries who had not participated directly in the Zazibona initiative saw a great 
deal of importance in the initiative and indicated support for it, especially with 
regards to the information sharing aspects. All participants in the study expressed 
support for the Zazibona initiative, with the general consensus being that “it has 
served as good way of sharing work, trust building and capacity building”. This 
support for the initiative indicated enthusiasm within SADC for harmonization 
initiatives and that a wider adoption of the Zazibona principles would be 
welcomed. 
 
There is a unique opportunity for SADC to use the experience that Tanzania has 
gained in the EAC initiative. Being a part of both the SADC and EAC region, 
Tanzania has obtained a wealth of knowledge from the harmonization activities in 
the relatively successful EAC harmonization initiative. With about 425 
registrations annually, the Tanzanian regulatory authority is relatively advanced. 
Although it was stated that the Tanzanian medicine legislation does not 
incorporate the SADC Protocol on Health currently, there is provision for 
information sharing and international cooperation within the legislation. Tanzania 
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has shown political will in participating in the SADC Heads of Agencies Forum, 
as well as participating in Zazibona joint assessments. Tanzania sees SADC 
harmonization as beneficial to “facilitate information sharing and hence facilitate 
quick registration of essential medicines”. 
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5.2.!Format!Harmonization!(CTD)!and!Model!Law!Adoption!
%
5.2.1. Survey Responses: 
TABLE XIII: Strategy of Format Harmonization and Model Law Adoption 
Question Respondent 4 Respondent 6 Respondent 9 
Strategies to 
improve 
harmonization 
Harmonization of 
Regulatory 
Framework 
Harmonization of 
Application Format  
Formal systems 
need to be 
implemented and 
controlled 
Adoption of 
regional guidelines 
by all countries 
Incorporation of 
the SADC 
Protocol on Health 
in your legislation 
Yes No Yes 
 
The three respondents listed in TABLE XIII indicated that regional guidelines, 
such as the AU Model Law, would need to be adopted to improve harmonization. 
Only two of the three of these listed respondents indicated that the SADC 
Protocol on Health was part of their country’s medicines legislation, which would 
need to be incorporated for SADC harmonization to occur. All except one 
respondent identified “format of applications” as a priority of harmonization. 
%
5.2.2. Interview Responses 
One interviewee noted that the “thing that is... going to help [harmonization] is the 
Model Law” (Interviewee 1, SARPAM). A SADC interviewee stated that 
“[SADC] harmonization processes in as far as medicines are concerned are 
governed by what is found in the Protocol on Health” (Interviewee 2, SADC). 
However, not all of participants in the survey indicated that their medicines 
legislation included the SADC Protocol on Health.  
 
Another interviewee involved in harmonization activities indicated that there is a 
big drive from industry for application format harmonization as it is “easier for 
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the industry to submit their dossier straight on one set of requirements”, especially 
for GMP inspections and application formats (Interviewee 3, AMRH Initiative).  
 
5.2.3. Discussion 
The adoption of the AU Model Law will enable SADC regulatory authorities to 
be able to share information between countries and adopt the decisions of other 
regulators within SADC. Although medicines legislation is needed to be country-
specific to ensure sovereignty and to deal with local challenges, the basis of the 
law should allow for harmonization. 
 
Although SADC countries have agreed to adopt the CTD format for registration 
applications, its implementation is still limited in some countries. Adopting the 
format will enable pharmaceutical companies to submit applications to many 
countries within SADC, increasing market access and leading to wider availability 
and accessibility of medicines. Adopting the CTD format will also enable 
technical working groups to coordinate work-sharing initiatives easier and more 
efficiently.  
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5.3.!Redirect!Focus!of!Harmonization!
 
5.3.1. Survey Responses 
TABLE XIV: Strategy of Redirecting Focus  
Question Respondent 5 
Strategies to improve harmonization Concentrate on scientific and technical 
matters in terms assessment of product 
applications and inspections 
6 out of the 7 survey respondents listed “technical regulatory requirements” as a 
priority area for harmonization. Respondent 5 stated that the focus on 
harmonization should be on “scientific [and] technical matter” instead of 
“legislative frameworks and registration processes”. Due to the different 
capacities of the SADC regulatory authorities, another respondent stated “detail to 
which each country should decide to go as far as regulation of medicines is 
concerned will depend on level of development, staffing available and facilities 
available”. 
 
5.3.2. Interview Responses 
The theme emerged that with successful harmonization, highly developed 
regulatory authorities will be able to empower less developed ones.  As one 
participant during a face-to-face interview indicated, “that’s what we want to see – 
countries helping one another” (Interviewee 3, AMRH Initiative).  
 
5.3.3. Discussion 
SARPAM at a regulatory conference in 2013 discussed that regulatory 
harmonization should first focus on “low-hanging fruits such as information and 
work sharing” (65). This recurring theme that emerged in the study included the 
view to focus on harmonization of technical requirements rather than broader 
legislation. Although it is hoped that harmonization in the SADC region could 
lead to a central regulatory authority (see TABLE I on Page 16), until capacity is 
increased through initiatives like establishing Regional Centres of Regulatory 
Excellence (RCOREs), the first step to harmonization would be convergence 
through information sharing.%  
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5.4.!Regulator!Initiatives!outside!of!the!SADC!Secretariat!
%
5.4.1. Survey Responses 
TABLE XV: Strategy of Regulator Initiatives 
Question Respondent 5 Respondent 7 
Perception of the 
Zazibona initiative 
Good model that all SADC 
states should adopt 
Support the initiative 
Strategies to improve 
harmonization 
- Strategize according to 
country maturity 
%
TABLE XV above illustrates the support that respondents showed for the 
Zazibona initiative, which, as detailed on Page of 19 this report, was constructed 
outside of the SADC Secretariat’s control. Participants in Zazibona took the 
initiative to coordinate harmonization activities without the SADC Secretariat, 
allowing greater flexibility to work according to country maturity and ability, as 
suggested by Respondent 7 as a strategy to improve harmonization.  
%
5.4.2. Interview Responses 
To address the barrier of lack of coordination by the SADC Secretariat, two 
participants who were part of regulatory harmonization initiatives indicated that 
for SADC harmonization to occur, countries would have to take the initiative to 
coordinate their own meetings and activities, while still falling under the SADC 
umbrella. One interviewee explained that “if you want anything to move as a 
region, it makes it a lot easier once it is moved from SADC… [Efforts should be 
coordinated] through SADC but [countries should not have] to wait for their go-
ahead… so there is need to shift the power of decision making” (Interviewee 1, 
SARPAM). The interviewee also added that regulatory authorities “are not at the 
same level and when it comes to expertise... they can benefit from those countries 
that have” (Interviewee 1, SARPAM). 
 
 The SADC interviewee confirmed that this is an ideal situation and that SADC 
“encourage[s] countries to partner amongst themselves. They should be free to 
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recognise the strengths of each-other and share information on their own using 
their levels of sovereignty and only using [SADC] to coordinate where necessary” 
(Interviewee 2, SADC).  
 
Regarding the success of the Zazibona initiative, the SADC interviewee indicated 
that “it is up to them now to share with us their experiences and we can see how 
then we can accommodate it in a SADC-wide programme… So the way forward 
is simply for countries to be able to have joint initiatives and secretariat facilitates 
and that’s what brings integration in the end” (Interviewee 2, SADC). 
 
5.4.3. Discussion 
This strategy of regulatory authorities initiating harmonization activities would be 
useful in addressing the barrier of lack of leadership within the SADC Secretariat. 
It would result in a higher chance of sustained participation, as countries would 
have a sense of ownership of the harmonization activities and not have these 
imposed by the Secretariat. Activities could also be tailored in accordance with 
specific country needs of those participating. Moving with a subset of countries 
with similar goals and abilities would achieve favourable results, as shown with 
the Zazibona initiative. 
 
It is also imperative to involve the pharmaceutical industry in the process of 
harmonization, as the regulatory authority and industry should work together to 
achieve a common goal. Medicines harmonization activities should be adapted by 
regulators according to local circumstances. 
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5.5.!Capacity!Development!
%
5.5.1. Survey Responses 
TABLE XVI: Strategy of Capacity Development 
Question Respondent 7 Respondent 8 Respondent 9 Respondent 
10 
Benefit of 
Zazibona 
Information 
sharing 
Information 
sharing and 
capacity 
building  
Continued 
capacity 
building and 
work sharing 
Information 
sharing   
Strategies to 
improve 
harmonization 
Resources, 
skills, 
expertise and 
political will 
Establish 
Regulatory 
Authorities in 
all countries 
Training 
centres 
Identifying 
lead experts 
Capacity 
building 
Number of 
evaluators 
90 Internal 
110 External 
15 Internal  
50 External 
11 Internal 
9 External 
24 Total 
%
TABLE XVI above indicates that, regardless of number of evaluators in a 
regulatory authority, capacity building was seen as a key strategy needed to 
improve harmonization. As respondents listed in TABLE XVI indicated, this may 
be done through the Zazibona initiative, which enables information sharing.  
 
One participant in this study indication that “no strategies developed by any 
outsider could be implemented by any NRA in SADC if the necessary resources, 
skills, expertise and political will are not present.” Respondents reiterated the 
need to “build human resource capacity within Member States” and that the 
“establishment of training centres and modules for NRA technical staff” would 
help to enable harmonization. These themes were repeated constantly and reached 
saturation quickly.  
 
5.5.2. Interview Responses 
An interviewee from the AMRH Initiative stated that to increase capacity, 
countries should establish RCOREs. “The idea behind this is that it helps you to 
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help countries to work together through a training programme - for example we 
have started with it for the East African Community. And it is through that we are 
able to first and foremost build trust among the regulators themselves but also 
build capacity through work-sharing” (Interviewee 3, AMRH Initiative).  
 
5.5.3. Discussion 
A key strategy to address the issue of regulatory capacity in SADC is the 
establishment of RCOREs through the AMRH Initiative. For example, in January 
2016, a bill to amend the Medicines and Related Substances Act 101 of 1965 was 
approved and signed into law that will lead to the establishment of the South 
African Health Products Regulatory Authority (SAHPRA), which will be 
independent of the South African Department of Health, will manage its own 
finances through retention of fees and will have the required internal regulatory 
capacity with a lower reliance on external experts. The issue that South Africa 
now faces is how to rapidly develop evaluator skills that are a major requirement 
for SAHPRA to function well. To address this, the country is undergoing an 
exercise to establish an Institute for Regulatory Sciences (IRS) in order to develop 
human resources to strengthen internal capacity required under the new SAHPRA 
framework, as well as to support regulatory capacity building within the wider 
SADC region. The IRS has undergone a pilot phase in which technical staff from 
the current regulatory authority, the Medicines Control Council, industry and 
other sectors of healthcare and science were successfully trained to be evaluators 
(65).  
 
The SADC Protocol on Health proposes “Centres of Excellence” which would 
allow for pooled resources and increase in capacity for member states. There is 
also a focus on reduction of counterfeiting, improving quality management and 
GMP (24). The AMRH Initiative aims to establish “harmonized curricula”. It is 
developing modules to be included in the curricula that should be adapted to meet 
the specific needs of the various SADC countries. This will be a big step in 
addressing the lack of regulatory capacity in the SADC region (65). 
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5.6.!Convergence!over!Harmonization!
%
5.6.1. Survey Responses 
TABLE XVII: Strategy of Convergence over Harmonization 
Question Respondent 7 Respondent 9 
Benefit from 
harmonization 
No - Convergence would 
be more useful 
- 
Strategies to address 
harmonization 
Strategies are developed by 
each regulator based on in 
country maturity 
Establishment of platform 
for secure information 
sharing 
%
It was also suggested for regulatory authorities to “mov[e] with a [group] of 
countries that have similar systems” and that “strategies [should be] developed by 
each regulator based on in country maturity” to achieve harmonization. One 
respondent stated that “convergence between NRAs would be a more useful tool 
within SADC than harmonisation” and that total harmonization would not be 
possible. The respondent indicated that convergence of guidelines and information 
sharing would be a more useful activity in the region. 
 
5.6.2. Interview Responses 
A SADC interviewee stated that “member states that are well-developed should 
not stop and wait for others – they should go on but should allow others to 
develop as well. So member states will move at their own levels but.. at the end of 
it all, we have harmony” (Interviewee 2, SADC). The participant also indicated 
that the “detail to which each country should decide to go as far as regulation of 
medicines is concerned will depend on level of development, staffing available, 
facilities available and the policies and political orientation” (Interviewee 2, 
SADC).  
 
Another interviewee indicated that harmonization efforts should aim for 
“standardization” but that “that’s a pie in the sky [and it is] better to talk about 
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convergence – coming together to an agreement” (Interviewee 1, SARPAM), as 
the interviewee saw this as a more realistic scenario.  
 
5.6.3. Discussion 
Convergence has a broader view than harmonization, focusing on the practicality 
of harmonization, rather than the standards and formats involved. The responses 
received from the more advanced regulatory authorities implied that these 
countries saw more value in convergence at this stage, in order to open the door to 
SADC harmonization but not at the cost of global harmonization standards and 
practices. These countries, who had surpassed minimum standards set out for 
harmonization, may be able to provide guidance to other less developed 
regulatory authorities through harmonization initiatives as “observers” rather than 
full participation, which may be viewed as being too time-consuming. 
 
In order to address the high demand placed on regulatory authorities with generic 
medicines approval, a group of regulators have launched the International Generic 
Drug Regulators Pilot (IGDRP), aimed at regulatory convergence and 
cooperation. Results of the pilot will inform decisions on establishing a more 
permanent information and work-sharing arrangement as part of broader 
international efforts related to regulation of medicines. The success of the 
initiative will require the support of industry as well as other stakeholders 
interested in promoting access to affordable, quality generic medicines (66). 
 
Regulatory authorities from Australia, Brazil, Canada, the EU, the Republic of 
Korea, Singapore, Switzerland and the United States as well as the WHO (being 
the secretariat of the pilot) met in Ottawa in October 2011 to explore opportunities 
for collaboration. It was recognised that information sharing is a key area of 
regulatory convergence, including the need to establish electronic platforms for 
non-confidential data and secure platforms for exchange of confidential data (66). 
 
It was also recognised that industry participation would be key in ensuring 
regulatory convergence, as applications for medicines registration would need to 
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be filed with a number of regulatory authorities. A possible barrier to this in the 
SADC region would be that different regulatory authorities currently have 
different requirements for Active Pharmaceutical Ingredient (API) quality. With 
South Africa recently increasing requirements relating to approval of API sources, 
the other countries in SADC would be required to increase API quality controls. 
The industry may not be interested in applying for marketing authorisation in 
countries that have stricter controls than others, unless there is attractiveness of 
high market demand for the medicine.  
 
At the above-mentioned meeting of regulatory authorities, a higher level of 
regulatory control and standards was anticipated to be the end results of 
convergence. An issue that was seen as a barrier is the risk of divergence when 
post-registration amendments are submitted separately to each authority. The 
complexity in establishing a collaborative review system was acknowledged, but 
it was seen that benefits would outweigh the risks (66). 
 
A formal governance structure and terms of reference were first developed, 
followed by operating procedures and definitions. It was decided to focus on 
generics before moving to biosimilars at a later stage. Convergence on 
requirements for API master files and biowavers is needed if SADC convergence 
is to occur%(12). 
 
There is going to be a high level of collaboration between the IGDR and the 
WHO Prequalification Programme to align requirements under IGDR 
jurisdictions. It is suggested that the SADC region also aligns with the WHO 
Prequalification Programme. Most participants in the study indicated that their 
respective countries had been involved in the WHO Prequalification Programme. 
South Africa has recently joined the IGDR and thus may bring this expertise to 
SADC. If regulatory requirements are aligned with the ICH, such as with the 
IGDR, it will be a possibility to converge with international organizations. This in 
turn will lead to even wider market accessibility and cheaper generic prices. The 
close integration of the regulatory authorities involved in the Zazibona initiative 
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with the WHO Prequalification Programme is a positive step to integrating with 
WHO and thus international standards (66). 
 
It is suggested that the EU’s Decentralised Procedure be used as an information 
sharing method for third part Regulatory Authorities. Consent is received from the 
applicant to share confidential information between the authorities (66). The 
mechanisms for scientific opinion formed by the EMA with the WHO on products 
intended for use outside of the European Union, as discussed on Page 10 of this 
report, may also be used for this purpose (34). 
 
 
  
Page%|%64%%
%
Chapter!6!–!Conclusion!
 
The purpose of the research was to evaluate the current states of medicines 
regulatory harmonization within the SADC region, as well as perceived barriers to 
harmonization and strategies to address these.  
 
It was found that the current state of medicines regulatory harmonization is one in 
which specific countries interested in harmonization are beginning to evolve best 
practices and convergence on registration issues. There appears to be a great deal 
of enthusiasm towards medicines regulatory harmonization from most of the 
regulatory authorities in the SADC region, regardless of size and capacity of the 
authorities. However, harmonization progress has been slow. The priority would 
be for countries to first adopt minimum standards before harmonization can be 
undertaken.  
 
Through the face-to-face interviews and questionnaire responses, a number of 
barriers to harmonization were identified and strategies to address these were 
suggested. The study showed that barriers to SADC regulatory harmonization 
perceived by participants include governance and leadership within the SADC 
secretariat, with red tape hindering progress of discussions under the SADC 
umbrella and forcing countries to create their own harmonization initiatives. 
Capacities of regulatory authorities was a major barrier identified, with the 
number of staff and products registered annually differing greatly between SADC 
countries. A lack of financial resources to undertake harmonization activities was 
noted as a barrier. Lack of political will to commit and follow through with 
activities and weak intra-SADC relationships due to diverse cultures and 
languages spoken in the SADC region were noted. Along with this, risk-benefit 
analysis differences as well as different guidance documents and legal 
frameworks were major perceived barriers.  
 
Strategies to address these barriers that emerged from the study included using 
EAC and Zazibona initiatives as models for harmonization activities, especially 
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with regards to information sharing. It was suggested that adoption of the CTD 
format be prioritized, as well as that the AU Model Law adoption be adopted by 
all SADC member states in order to allow technical working groups to co-ordinate 
initiatives easier. It was suggested that the focus of regulators be upon information 
sharing initiatives as a first step to harmonization.  The lack of coordination from 
the SADC secretariat has led to the need for regulators to take initiative and work 
outside of the SADC on harmonization activities. Capacity development through 
the establishment of RCOREs is imperative for harmonization to occur. and 
funding through the World Bank agreement.  
 
Harmonization in the SADC region would mean a more efficient and streamlined 
system of dialogue between countries, encouraging a common regulatory 
language, best practices and adaptation to the increasing globalization of the 
pharmaceutical industry. However, it was suggested by participants in this study 
that the focus of harmonization activities needs to be redirected and that 
convergence should be achieved before harmonization. This would mean a more 
practical approach to allow for different capacities of regulators in the region, as 
well as other barriers highlighted in the research. As it stands, there is insufficient 
capacity for SADC to completely harmonize its medicines regulation. It is 
therefore suggested that countries converge their regulatory activities and 
gradually move towards complete harmonization in the SADC region, and 
eventually in Africa as a whole in the future. 
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Appendix!1!–!Table!of!Themes!and!Contributing!
Factors!
%
Topic Themes Categories 
Barriers to Medicines 
Regulatory 
Harmonization 
Governance and 
Leadership within 
SADC 
Inertia 
Lack of Coordination 
Lack of Prioritization 
Capacities of 
Regulatory Authorities 
Limited human resources 
Different levels of 
development 
Maturity of regulation 
Different levels of 
expertise 
Financial Resources  Different socioeconomic 
status 
Lack of funds to take part 
in activities 
Political Will Lack of perceived benefit 
Intra-SADC 
Relationships 
Diverse cultures and 
language 
Different heritage, 
tradition and cultures 
Risk-Benefit Analysis 
Difference 
Each regulator has final 
decision with different 
interpretation and 
priorities 
Legal Framework Lack of adoption of CTD 
Format  
Out-dated SADC 
framework 
Lack of faith in 
harmonization guidelines 
Lack of enabling 
legislation 
Strategies to Address 
Barriers 
EAC and Zazibona as 
Models 
Reference guide for 
standards 
Variations in capacity of 
regulators 
Tanzania experience 
Format Harmonization 
(CTD) and Model Law 
Adoption 
Information sharing and 
transparency 
Cooperation 
Market access for industry 
Easier work sharing 
initiatives 
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Redirect Focus  Scientific and technical 
matter over legislation 
Prioritise information and 
work-sharing  
Regulatory Initiatives Power of decision making 
Coordinate outside of 
SADC but under umbrella 
World Bank Agreement Funding for 
harmonization 
SADC harmonization 
goals 
Capacity Development Centres of Regulatory 
Excellence 
Harmonized Curricula 
Convergence over 
Harmonization 
API and Biowaiver 
requirements 
Post-registration 
amendments 
International Generic 
Drug Regulators Pilot 
Global Regulation Globalisation of industry 
Capacity building and 
transparency 
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Appendix!2!–!Questionnaire!
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Barriers to Medicines Regulatory Harmonization Questionnaire%
Instructions:"For"open"responses,"write"the"response"in"space"provided.""For"Yes/No"or"
questions"with"options,"please"tick"the"appropriate"box."%
Respondent Details 
Name:              __________________________            
Designation:     __________________________ 
Organization:    __________________________ 
Date:                 __________________________ 
1 Does your country have specific legislation and supporting regulations for the 
registration, regulation and control of medicines and health products? 
 
       Yes     No  
 
2 In which year was the legislation first promulgated and when was it last amended? 
• Created:           ______         Last amended: ______ 
 
3 Does the medicines legislation: 
• Make provision for the establishments of a National Regulatory Authority 
(NRA)? 
 
 Yes     No  
 
• Have a definition for a medicinal product, a medical device, in-vitro 
diagnostic (IVD) or other category of product? 
 
       Yes     No  
 
• Give the NRA the power to carry out inspections of pharmaceutical 
products and practices? 
 
       Yes     No  
 
• Give the NRA the power and responsibility to deal with non-compliant 
products or companies? 
 
       Yes     No  
 
4 Does the NRA conduct: 
• Registration of medicines? 
 
       Yes     No  
 
• Inspections of manufacturing sites? 
       Yes     No  
 
5 Are regulatory activities organized and performed at a central level of the country? 
 
       Yes     No  
What was the total number of drugs registered in 2014:  
• Generics:                       
• New Chemical Entities:  
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6 What is/are the source/s of funding for the NRA (please tick all that apply): 
 
 Government                  
 Fees levied by the NRA   
 Industry      
 Donors    
 Other (please specify) _____________        
 
7 Does the legislation incorporate the objectives of the SADC Protocol on Health 
 
      Yes     No  
 
8 Is there provision in your country’s legal framework for (please tick all that apply): 
 
 Harmonization in the SADC Region   
 International Cooperation                  
 Information Sharing                            
 
9 Does the NRA have cooperative agreements/ Memoranda of Understanding 
(MOU) with other NRAs? 
 
      Yes     No  
 
      Please Specify:___________________________________ 
 
10 How many evaluators does the NRA employ: 
 
• Internally:  ________ 
 
• Externally: ________ 
 
11 Has the NRA participated in training on the WHO-Prequalification, ICH, SADC or 
other guidelines? 
 
       Yes     No  
 
       If Yes, please specify: 
_____________________________________________ 
 
12 Does your country participate in activities involving (please tick all that apply): 
 
 Issuing of CPP certificates following a documented procedure 
 PIC/s inspections 
 WHO External Quality Assurance Assessment Scheme (EQAAS) 
 WHO Drug Safety Monitoring Programme 
 INCB’s international monitoring operations on control of Narcotics and 
Psychotropic       Substances and their Precursors 
 
13 
 
 
 
 
Has the NRA been involved in Regulatory Harmonization activities or information 
sharing with other SADC countries (please specify) – working groups, forums: 
 
      Yes     No  
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14 If the NRA has been involved in Regulatory Harmonization activities, what 
problems were encountered and how were they resolved, if applicable?  
• ___________________________________________________________ 
• ___________________________________________________________ 
• ___________________________________________________________ 
• ___________________________________________________________ 
• ___________________________________________________________ 
 
15 Do you think that your country and other SADC countries would benefit from 
Regulatory Harmonization within the SADC Region?  
 
      Your country:                  Yes       No  
 Please expand: 
_______________________________________________________ 
      Other SADC countries:   Yes       No  
Please expand: 
_______________________________________________________ 
      
 
16 What do you think your country will gain most from harmonization, if applicable? 
 
      
_________________________________________________________________ 
 
17 What would you consider to be priority areas for harmonization, in your opinion: 
 
 Inspections 
 Law enforcement activities 
 Format of applications 
 Structure of Regulatory Authority 
 Technical regulatory requirements 
 Other (please 
specify)_____________________________________________ 
 
18 Which countries do you recognize and/or uses regulatory decisions, reports 
(inspection, evaluation, vigilance), guidance or information from 
 
• Within SADC:        
________________________________________________ 
 
• Outside of SADC:  
________________________________________________ 
 
19 Have you registered products based on registration in other countries: 
 
• Within SADC?:        Yes       No    If Yes, 
specify:_____________________ 
 
• Outside of SADC?:  Yes       No    If Yes, 
specify:_____________________ 
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20 What are your perceptions or experiences of the Zazibona initiative? 
_________________________________________________________________ 
_________________________________________________________________ 
 
21 How do you think your country could benefit from the initiative?              
_________________________________________________________________ 
_________________________________________________________________ 
22 What do you perceive as the major barriers to harmonization in the SADC region? 
• ___________________________________________________________ 
• ___________________________________________________________ 
• ___________________________________________________________ 
• ___________________________________________________________ 
 
23 What strategies are needed to improve regulatory harmonization in the SADC 
Region?  
• ___________________________________________________________ 
• ___________________________________________________________ 
• ___________________________________________________________ 
• ___________________________________________________________ 
 
 
Any%other%comments:%
________________________________________________________________________%
 
!
! !
Thank!you!for!your!
participation!!
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Appendix!3!–!Questionnaire!Responses!
Swaziland)*)FF)(Respondent)4) South)Africa)*)DM)
(Respondent)5)
South)Africa)*)AK)
(Respondent)6)
South)Africa)*)JG)
(Respondent)7)
Tanzania)*)SK)(Respondent)8) Zambia)*)ZM)(Respondent)9) Zimbabwe)*)LG)
(Respondent)10)
1 Y Y Y Y Y Y Y
Created) 1929 1965 1965 1965 2003 2013)(repealed)2004) 1969
Last)Amended In)parliament)for)repeal 2003 2014 2015 N/A N/A 2001
Does)the)
medicines)
legislation
Make)provision)for)
the)establishments)
of)NRA
Y Y Y Y Y Y Y
Have)a)definition)
for)a)medicinal)
product,)IVD)etc
Y Y Y Y Y Y Y
Give)the)NRA)the)
power)to)carry)out)
inspections
Y Y Y Y Y Y Y
NRA)power)and)
responsibility)to)
deal)with)non*
compliance
Y Y Y Y Y Y Y
Does)the)NRA)
conduct
Registration)of)
medicines
N Y Y Y Y Y Y
Inspections)of)
manufacturing)sites
N Y Y Y Y Y Y
Y Y Y Y Y Y Y
Generics 0 400 = 526 425 370 143)TOTAL
NCEs 0 26 = 26 = 4
Government)))))))))))))))))Y Y Y Y Y Y N
Fees)levied)by)the)
NRA))
N Y N N Y Y Y
Industry N N N N Y N N
Donors))) N N N N Y Y N
Other) N N N N N N N
7 Y N N Y N Y =
Harmonization)in)
SADC)
Y N N N N Y N
International)
Cooperation)))))))))))))))))
Y N N Y Y Y N
Information)Sharing)))))))))))))))))))))))))))Y N N Y Y N N
Question
6
8
Questionnaire)Responses
2
3
4
5
Does)your)country)have)legislation)
and)supporting)regulations)for)the)
registration,)regulation)and)control)
of)medicines)and)health)products?
In)which)year)
was)legislation:
Are)regulatory)activities)organized)
and)performed)at)a)central)level)of)
the)countrytotal)drugs)
registered)2014
What)is/are)the)
source/s)of)
funding)
Does)the)legislation)incorporate)
objectives)of)SADC)Health)Protocol
Is)there)
provision)in)
your)country’s)
legal)framework)
for)
9 N Y)=)Swissmedic Y)=)Swissmedic)and)MHRA Y)=)SwissMedic;)
Switzerland,)USFDA;)USA,)
MHRA);United)Kingdom
Y)=)In)the)framework)of)
Harmonization)within)East)African)
Community
N)=)But)have))working)
relationship)with)Zimbabwe,)
Botswana)and)Namibia)under)
the))ZAZIBONA)initiative
N
Internally 2 12 = 90 15 11 24
Externally = 22 = 110 50 6)from)other)department)
within)institution,)3)from)
outside
0
11 Y)=)Ministry)participates)in)the)
development)of)SADC)
guidelines,)SADC)and)ICH)
trainings)in)GMP)and)GCP
Y)=)WHO)Pre=Qualification)
and)SADC
Y)=)WHO)and)ICH Y)=)[WHO=Prequalification,)
ICH,)SADC].)SADC)
Guidelines)however)found)
to)be)outdated)and)no)
longer)in)line)with)
international)best)practises
Y)=)Prequalification)of)Medicines)
Programme)
Y)=)WHO)prequalification)
annual)training,)WHO)
organised)training)workshops)
on)dossier)review,)SADC)
organised)workshops)on)
dossier)evaluation.
Y
Issuing)of)CPP)
certificates)
N Y Y Y Y Y Y
PIC/s)inspections N Y Y Y N N N
WHO)EQAAS N N N Y Y Y Y
WHO)Drug)Safety)
Monitoring)
Programme
Y N N Y Y Y Y
INCB Y Y Y Y Y Y Y
13 Y)=)take)part)in)the)SADC)
Regulators)Forum)and)ICH)RHI)
and)ICH)International)
Pharmaceuticals)Regulators)
Forum)(IPRF)))
Y)=)Initially)yes,)but)now)
only)as)an)invited)observer)
at)ZAZIBONA
= Y)=)ZAZIBONA)work)sharing)
initiative.)All)WHO)
Harmonization)initiatives)
and)workshops)
Y)=)SADC)Harmonization)Initiative=)
Heads)of)Agencies)forum
Y Y
10
12
Does)the)NRA)have)cooperative)
agreements/)Memoranda)of)
Understanding)(MOU))with)other)
NRAs
How)many)
evaluators)does)
the)NRA)employ
Has)the)NRA)participated)in)training)
on)the)WHO*Prequalification,)ICH,)
SADC)or)other)guidelines
Does)your)
country)
participate)in)
activities)
involving)
Has)the)NRA)been)involved)in)
Regulatory)Harmonization)activities)
or)information)sharing)with)other)
SADC)countries)
14 The)challenge)is)that)the)
country)has)not)started)
registering)products)coming)
into)its)market,)only)listing)has)
been)done)thus)far,)so)the)
training)and)skills)gained)and)
not)be)implemented)
immediately.)The)new)
Medicines)and)Related)
Substances)Control)Bill)once)
enacted)provided)for)the)
registration)of)medicines)and)
the)establishment)of)a)NMRA
•)Legislation)differences
•)Differing)Assessment)
standards
•)Perceived)levels)of)
expertise
•)Registration)processes
•)Trust
•)Relying)on)the)decisions)
made)by)another)
regulatory)authority
•)Application)of)
harmonization)strategies)
(1st)world)countries)vs.)
3rd)world)countries)
•)SADC)Guidelines)is)
outdated.))Decision)then)
taken)to)use)WHO)
Guidelines)which)address)
the)same)topic
•)Harmonization)can)only)
be)discussed)with)certain)
SADC)countries)due)to)the)
large)gap)between)the)
implemented)regulatory)
systems)of)the)RSA)
Regulator)versus)those)of)
some)of)our)SADC)
colleagues.))
•)The)final)regulatory)
decision)still)remains)with)
each)specific)Regulator.
•)Timely)National)registration)of)the)
products)after)joint)assessments
•))Release)of)regulatory)officials)to)
participate)in)joint)activities.)The)
problem)was)resolved)by)
recruitment)of)National)Medicines)
Regulatory)Officers)in)all)NMRAs
•)Cost)of)undertaking)the)
activities
•)Different)levels)of)capacity)at)
different)regulatory)authorities)
•)Slow)progress)
•)Wide)variation)of)the)
countries)with)respect)to)
regulatory)systems)
Do)you)think)
that)your)
country)and)
other)SADC)
countries)would)
benefit)from)
Regulatory)
Harmonization)
within)the)SADC)
Region
Your)country Y)=)The)country)would)not)have)
to)reinvent)the)wheel)but)can)
recognize)the)work)done)by)
other)member)states)in)the)
region
Y Y N)=)Convergence)between)
NRA)would)be)a)more)
useful)tool)within)SADC)
than)harmonisation
Y)=)Will)facilitate)information)sharing)
and)hence)facilitate)quick)
registration)of)essential)medicines
Y=)It)would)reduce)duplication)
of)work)thereby)reducing)on)
time)it)takes)to)processes)
application.)Each)Agency)could)
benefit)from)the)expertise)and)
skill)that)may)be)present)in)
other)agencies.
Y
Other)SADC)
countries
Y)=)Country)can)benefit)from)
working)sharing)such)as)joint)
dossier)evaluation)and)joint)
inspections)to)expedite)product)
registration)in)their)member)
states
Y Y N)=)Convergence)between)
NRA)would)be)a)more)
useful)tool)within)SADC)
than)harmonisation
Y)=)Other)countries)would)benefit)
from)current)regulatory)capacity)in)
Tanzania
Y)=)it)would)serve)as)a)capacity)
building)process
Y
16 It)will)facilitate)recognition)of)
work)done)by)other)member)
states)and)reduce)work)in)
country)and)it)will)facilitate)
Improve)on)assessment)
standards)and)elimination)
of)duplication)of)work
Harmonization)has)many)
benefits)including)
knowledge)sharing,)
allowing)for)work)sharing)
N/A = •)Work)sharing
•)Skills)development
•)Confidence)building)
Easier)to)share)
information)and)to)
collaborate))
Inspections Y Y Y N Y Y N
Law)enforcement N Y N Y Y N N
Format)of)
applications
Y N Y Y Y Y Y
Structure)of)NRA N Y Y N Y N N
Technical)
regulatory)
requirements
Y Y Y N Y Y Y
Other) N N N N N N N
17
15
What)would)
you)consider)to)
be)priority)areas)
for)
harmonization,)
in)your)opinion
If)the)NRA)has)been)involved)in)
Regulatory)Harmonization)activities,)
what)problems)were)encountered)
and)how)were)they)resolved,)if)
applicable
What)do)you)think)your)country)will)
gain)most)from)harmonization,)if)
applicable
Within)SADC Zimbabwe,)Tanzania,)South)
Africa
None None None None Zimbabwe,)Botswana)and)
Namibia)))))))
ZAZIBONA)participating)
countries)
Outside)of)SADC Whole)ICH)Region EU,)CANADA,)TGA,)FDA PIC/s)countries Inspection)reports)from)
PIC/S)member)countries
ICH)Countries) = ICH)countries)
Within)SADC N N = N N Y N
Outside)of)SADC N N = No)specific)data)available)as)
inspections)is)just)one)of)
the)regulatory)
requirements)to)register)a)
medicine.
Y)=)ICH)Countries)and)WHO)through)
Collaborative)registration)
arrangements
= Y)=)registrations)in)ICH)
countries;)WHO)PQ)
20 It)is)a)great)initiative)within)the)
SADC)Region)to)speed)up)
market)authorization)and)it’s)a)
great)learning)forum)for)the)
observers)as)well.)All)SADC)
member)states)should)take)part)
in)this)initiative,
A)very)good)initiative)by)
the)four)countries)and)
need)to)be)supported)by)
SADC)and)a)good)model)
that)should)be)inclusive)of)
all)SADC)member)states
I)have)not)had)any)
personal)exposure)to)or)
interaction)with)the)
Zazibona)inititative
Support)the)initiative I)personally)participated)in)one)
session)(March)2015).)Assessment)
sessions)are)conducted)by)using)
stringent)regulatory)requirements.)
Sessions)provides)opportunity)for)
capacity)building)of)regulators)from)
countries)with)limited)regulatory)
capacity.=ZaZiBoNa)assessments)
provides)starting)point)for)joint)
assessment)and)inspection)activities)
in)the)SADC)region)
It)has)served)as)good)way)of)
sharing)work,)trust)building)
and)capacity)building.)
Zimbabwe)is)one)of)the)
founding)countries)and)
participate)fully)
21 It’s)a)learning)initiative)and)it)
would)help)in)recognising)the)
work)done)by)this)group)and)
not)have)to)redo)the)work)in)
country)once)we)start)
registration)of)medicines
Sharing)of)expertise)and)
scarce)skills)within)the)
region.)Short)turn=around)
times)in)product)
registration)and)
inspections
N/A Information)sharing The)initiative)could)provide)the)
following)opportunities)to)my)
country:)Receipt)and)sharing)of)
regulatory)information,)Work)
sharing)with)other)regulators)and)
hence)helps)in)reducing)workload,)
Capacity)building)for)regulatory)
officers,)Availability)of)good)quality)
medicines)in)the)regional)market)
and)hence)reduce)prevalence)of)
substandard)medicines
Continued)capacity)building)
and)work)sharing.)It)would)also)
lead)to)recognition)of)work)by)
other)countries)including)
report)sharing)and)decisions
Easier)to)share)
information)and)to)
collaborate))
22 •)Differences)in)the)Legal)
frameworks
•)Differences)in)the)application)
format)(CTDs)
•)Issues)of)sovereignty
•)Legislation)differences
•)Differing)Assessment)
standards)
•)Perceived)levels)of)
expertise
•)Registration)processes
•)National)pride)
•)Trust)building)amongst)
regulatory)authorities
•)Differences)in)or)
absence)of)national)
regulatory)authorities
The)different)levels)of)
Regulatory)Development)
and)maturity)of)the)various)
National)Medicines)
Regulatory)Authorities)
within)SADC.
•)Dependency)on)external)technical)
and)financial)support)in)regional)
activities
•)Lack)of)clear)understanding)of)
harmonization)and)benefits)of)
harmonization)in)Partner)States
•)Some)countries)in)the)region)do)
not)have)well)established)medicines)
regulatory)systems
•)Language)barriers)in)few)countries)
(e.g)Mozambique,)Angola)and)DRC)
•)Use)of)different)guidance)
documents
•)Difference)in)capacity)levels)
of)NMRAs
•)Funding)for)joint)work
•)Levels)of)development)
and)systems)among)SADC)
countries)
•)Capacity)limitations)in)
the)SADC)Member)States)
to)implement)agreed)
positions)/)decisions
18
19 Have)you)
registered)
products)based)
on)registration)
in)other)
countries
Which)countries)
do)you)
recognize)or)use)
regulatory)
decisions,)
reports,)
guidance)or)
information)
from
What)are)your)perceptions)or)
experiences)of)the)Zazibona)
initiative
How)do)you)think)your)country)could)
benefit)from)the)initiative
What)do)you)perceive)as)the)major)
barriers)to)harmonization)in)the)
SADC)region
23 moving)with)subset)of)
countries)that)have)
similar)systems)
•)Build)human)recourse)
capacity)within)Member)
States)
•)Strategies)are)developed)
by)each)Regulator)based)on)
in)country)maturity.
•)No)strategies)developed)
by)any)outsider)could)be)
implemented)by)any)NRA)in)
SADC)if)the)necessary)
resources,)skills,)expertise)
and)political)will)are)not)
present.
Formal)systems)need)to)
be)implemented)and)
controlled
•)Concentrate)on)
scientific/)technical)matter)
in)terms)assessment)of)
product)applications)and)
inspections
•))And)let)individual)
regulatory)authorities)deal)
with)legislative)
frameworks)and)
registration)processes)
•)Harmonization)of)Regulatory)
Framework
•)Harmonization)of)Application)
Format)(CTDs/eCTDs)
•)Work=sharing)such)as)
ZAZIBONA
•)Facilitate/Support)establishment)
of)National)Medicines)Regulatory)
bodies)in)the)countries)lacking)such)
agencies
•)Establish)links)and)strengthen)
political)support)in)countries)on)
SADC)matters)and)specifically)
medicines)regulatory)harmonization
•)Establishment)and)strengthen)joint)
assessments)and)inspections)as)pilot)
projects)towards)the)overall)regional)
harmonization
•)Building)of)capacity)at)the)
Secretariat)to)facilitate)
harmonization)initiatives)
•)Adoption)of)regional)
guidelines)by)all)countries
•)Establishment)of)training)
centers)and)modules)of)NMRA)
technical)staff
•)Establishment)of)platform)
for)secure)information)sharing
•)Identification)of)lead)experts)
in)thematic)areas)within)the)
region.
What)strategies)are)needed)to)
improve)regulatory)harmonization)in)
the)SADC)Region
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PLAGIARISM!DECLARATION!TO!BE!SIGNED!BY!ALL!HIGHER!DEGREE!STUDENTS!
SENATE!PLAGIARISM!POLICY:!APPENDIX!ONE!
I,!Amanda!Calder!(Student!number:!875651)!am!a!student!registered!for!the!degree!of!Master!of!
Science!in!Medicine!(Pharmaceutical!Affairs)!in!the!academic!year!2016!
I!hereby!declare!the!following:!
! I!am!aware!that!plagiarism!(the!use!of!someone!else’s!work!without!their!permission!
and/or!without!acknowledging!the!original!source)!is!wrong.!
! I!confirm!that!the!work!submitted!for!assessment!for!the!above!degree!is!my!own!unaided!
work!except!where!I!have!explicitly!indicated!otherwise.!
! I!have!followed!the!required!conventions!in!referencing!the!thoughts!and!ideas!of!others.!
!
! I!understand!that!the!University!of!the!Witwatersrand!may!take!disciplinary!action!against!
me!if!there!is!a!belief!that!this!is!not!my!own!unaided!work!or!that!I!have!failed!to!
acknowledge!the!source!of!the!ideas!or!words!in!my!writing.!
!
Signature:!!!!! ! Date:!28!April!2016!
